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ABSTRACT  
Drinking vinegar is a popularly discussed remedy for relieving heartburn symptom, 
as can be read on many websites; however, there has been no scientific research or theory to 
support its efficacy.  This randomized, placebo-controlled, double-blind, cross-over research 
study tested the efficacy of the organic apple cider vinegar, with mother, on alleviation of the 
heartburn symptom related to Gastro-esophageal reflux disease (GERD).  A minimum of 
one week separated the four trial arms: chili (placebo), antacid after chili meal (positive 
control), vinegar added to chili, and diluted vinegar after chili meal.  Twenty grams of 
vinegar were used in both vinegar treatments, and 10 grams of liquid antacid were used in 
the antacid trial.  A five-point Likert scale and a 10-cm visual analogue scale (VAS) were 
used to assess heartburn severity during a 120 minutes testing time.  Seven of 15 recruited 
subjects' data was usable for statistical analysis (age: 39.6 ± 12.2 y, body mass index (BMI): 
29.4 ± 4.2 kg/m2, waist circumference: 36.4 ± 4.1 inch).  There was no statistically 
significant difference among the mean and incremental area-under-the-curve (iAUC) 
heartburn scores among different trials (Likert scale questionnaire p= .259, VAS 
questionnaire p= .659, iAUC Likert scale p= .184, iAUC VAS p= .326).  Seven participants 
were further divided into antacid responder (n=4) and antacid non-responder groups (n=3).  
Likert scale mean heartburn score and iAUC data in antacid responder group had significant 
finding (p= .034 and p= .017 respectively).  The significance lay between antacid and 
'vinegar added to chili' trials.  Effect size was also used to interpret data due to the small 
sample size:  Likert scale: mean heartburn score= .444, iAUC= .425; VAS mean heartburn 
score= .232, iAUC .611.  Effect size for antacid responder group was Likert scale: mean 
heartburn score= .967, iAUC= .936.  Future research is needed to examine whether 
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ingesting organic vinegar benefits alleviation of heartburn symptom related to GERD for 
people who do not respond well to antacid.   
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CHAPTER 1 
INTRODUCTION 
The United States reports the highest prevalence of 17.6 - 28.8% gastroesophageal 
reflux disease (GERD) during the last two decades, based on the questionnaires of 379 - 
1524 sample size compared to the Asia and the Europe (Ronkainen & Agreus, 2013).  One 
major cause of the GERD is the refluxing of stomach or intestinal contents back to the 
esophagus.  Heartburn is a chest-burning sensation which generates a discomfort at the 
substernal region, and it is one of the most common symptoms of GERD (Dore, Pedroni & 
Pes et al., 2007).   
Over-the-counter medications and home remedies are popular strategies to alleviate 
these symptoms (Rodriguez, Miner & Robinson et al., 1998; Collings, 2002).  In 1998, more 
than one billion dollars was spent on over-the-counter medications treating heartburn in the 
U.S., and since then the clinical problem of GERD has been increasing globally (Rodriguez 
et al., 1998; Hartono, Qua & Goh, 2011).  Gastric acid has been blamed as the source of the 
discomfort.  One of the most effective acid-suppression medications in today's market is the 
proton-pump inhibitor (PPI).  In 2009, the total sale of PPIs was approximately $13.6 billion 
worldwide (Gatyas, 2009).  However, there are concerns about long-term treatment with 
PPIs.  The therapy may create a dependency in that halting treatment induces rebound acid 
hypersecretion and makes it difficult to discontinue use (Reimer, Sondergaard, Hilsted & 
Bytzer, 2009).  On top of rebound acid hypersecretion, hip fracture, enteric infections, drug 
interaction, reduction of vitamin B12, and hypergastrinemia are also the safety issues relate 
to long-term PPI treatments (Hershcovici, Mashimo & Fass, 2011; Tari, 1997).  The risk of 
esophageal adenocarcinoma increases among the people who use PPIs chronically, having 
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GERD with erosive endoscopic findings or diagnosed with Barrett's esophagus (Lada, 
Niemam & Han et al., 2013; Erichsen, Robertson & Farkas et al., 2012). 
With the side effects of the acid-suppression medications in mind, the interest in 
studying dysfunction of the lower esophageal sphincter (LES) has increased.  Pharmacology 
has shifted its focus on treating GERD from acid suppressant such as PPIs in the last few 
decades to improving the function of LES, which is the key physiological anti-reflux 
mechanism in the body with the crural diaphragm (Hershcovici et al., 2011).   
It is thought that transient lower esophageal sphincter relaxation (TLESR) is the 
most mutual causal mechanism of GERD, especially for the patients who have non-erosive 
reflux disease (NERD) and do not respond to PPIs well (Hershcovici et al., 2011).  NERD 
patients have normal endoscopy findings and the majority of the GERD patients fall under 
this category.  For example, in the Asia-Pacific region up to 75% of GERD patients are in 
NERD group (Hartono et al., 2011).  It is suggested that the purpose of the TLESR is letting 
the gas out of the stomach.  Currently a great deal of research is focused on reducing the 
TLESR in order to reduce the acid reflux episodes or performing surgery to fix the 
deficiency of the LES (Crookes, 2006).  However, bloating of the stomach might be a 
possible side effect of the reducing TLESR approach, if the reason behind having TLESR is 
letting the gas out of the stomach, and surgery is not cost effective.   
In the esophagus, both chemical and physical reactions are used to clear the acidic 
content from the stomach due to reflux.  Saliva secretion is increased when the esophageal 
body senses acid because saliva acts as a buffer, which neutralizes the acid through chemical 
reactions (Crookes, 2006; Dutta, Agrawal & Mahmoud, 2010).  Collings and colleagues 
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successfully used calcium carbonate gum to neutralize the acid in the esophagus and relieve 
the heartburn symptoms after a meal without dramatically change the pH in the stomach 
(Collings, 2002), which is the main underlying source of many side effects of PPIs.  The 
physical process of clearing acidic content is through esophageal emptying by peristalsis 
(Crookes, 2006).  Research evaluated the effects of acidification on the esophageal motor 
activity by Corazziari et al. and Bontempo et. al., has demonstrated that, in the esophageal 
mucosa, there are acid sensitive receptors that can sense the change in the intraluminal pH.  
Acid infusion at the lower part of esophageal body could induce esophageal peristaltic 
contractions of the smooth muscle that are independent of swallowing, and these 
contractions are referred to as secondary peristalsis.  Furthermore acid infusion increased the 
frequency of dry and wet swallowing, which triggered the primary peristalsis.  The 
movement of this acid-induced primary peristalsis is longer in duration, bigger in amplitude 
(especially the upper third body), and lower in propagation velocity when compared to 
saline-infusion phase (Corazziari, Pozzessere, Dani, Anzini & Torsoli, 1978; Bontempo, 
Piretta & Corazziari et al., 1994).   
In general, patients with NERD condition have a hypersensitive esophagus 
compared to the asymptomatic ERD patients who have a hyposensitive esophagus.  NERD 
patients, besides acid reflux, the non-acidic content can also produce the symptoms of 
GERD (Hartono et al., 2011).  Without the acid in the reflux content, the acid-induced 
contraction is not stimulated, so the emptying of the esophagus does not occur.  This might 
be the underlying reason that PPIs don’t work well with this group of patients.  On the other 
hand, people with ERD who have a hyposensitive esophagus, even though the acid reflux 
has entered the lumen, the receptors in the esophageal mucosa are not responding to the 
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acid well, so the acidic content stays in the esophagus longer.  In this situation damage to the 
esophageal mucosa might take place.  Drinking organic vinegar is a popularly discussed 
remedy, which relieves heartburn symptom, on the website; however, there is no scientific 
research or theory to support its efficacy.  Vinegar is cost effective, simple, readily available, 
and there is no concern of rebound acid hypersecretion and other side effects previously 
mentioned that relate to long term PPI treatment. 
Purpose of Study 
 The purpose of this experiment was to test the efficacy of the apple cider vinegar on 
alleviation of the heartburn symptoms related to GERD, and provide scientific research for 
a popularly discussed remedy on the website. 
Hypotheses 
H1.  Compared to the both vinegar trials, the antacid trial shows significant 
alleviation of the heartburn sensation.  
H2.  Compared to the placebo trial, the vinegar trials do not show significant 
alleviation of the heartburn sensation. 
Definition of Terms 
• Acetic Acid: A weak strength and sharp flavored acid, which is the main component 
of vinegar.  Its chemical form is CH3COOH. The average acidity of vinegar is 5%. 
• Acid reflux: A condition in which the content of the stomach containing gastric acid 
flows back into the esophagus.  
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• Asymptomatic erosive reflux disease (ERD): Patients experience no discomfort of 
GERD symptoms, but endoscopy findings show damage of the esophageal mucosa 
because of acid reflux. 
• Esophageal adenocarcinoma: A type of cancer derived from glandular tissue of 
esophageal epithelia. 
• Gastroesophageal reflux disease (GERD): a chronic digestive disorder that stomach 
contents flow back into the esophagus through the lower esophageal sphincter (LES) 
causing symptoms of heartburn, chest pain, regurgitation, dry cough, nausea, sore 
throat, and feeling of a lump in the throat.  According to patients' endoscopic 
findings, GERD can usually be allocated into three categories: Non-erosive reflux 
disease (NERD), symptomatic and asymptomatic erosive reflux disease (ERD).  
• Heartburn: A chest-burning sensation which generates a discomfort at the sub 
sternal region. 
• Hypergastrinemia: An excess of gastrin, a gastric hormone stimulates secretion of 
gastric acid, in the blood. 
• Lower esophageal sphincter (LES): An area where the esophagus merges with the 
stomach and it relaxes during swallows.  From manometry perspective it is the high 
pressure zone which consists of two kinds of musculature.  
• Non-Erosive Reflux Disease (NERD): Patients who have GERD symptoms, but 
with normal endoscopy results, however histological test might show some changes 
of esophageal epithelium. 
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• Proton-pump inhibitor (PPI): A kind of medication that reduces gastric acid 
production. It is one of the most effective medicines available for treating acid-reflux 
on the current market. 
• Rebound acid hypersecretion: An increase in gastric acid secretion, which is more 
than pretreatment level, within two weeks after discontinuing of antacid treatment. 
• Transient lower esophageal sphincter relaxation (TLESR): A spontaneous relaxation 
of LES lasting 10 - 60 seconds that is independent of swallowing, but with 
simultaneous relaxation of the crural diaphragm.  TLESR is thought to be a natural 
pathway to vent air in the stomach, and also the most mutual causal mechanism of 
GERD. 
Delimitations and Limitations 
The symptom assessment of heartburn severity in this research was mainly based on 
each participant's subjective sensation.  Vinegar has a very distinctive smell and flavor 
although the effort had been made to mask its characteristic, some participants might still 
guess they were in the experimental trial, hence bias could arise.  Lacking of quantitative 
data, such as intraluminal pH and pressures readings of the esophagus, and the possibility of 
participants noticed vinegar and knowing they were in the experimental trials might play a 
role during the symptom assessments.  Many participants had early work shifts, and some 
needed to get up at 4 am.  Even though all participants stated with fasting until 8 am on the 
study day; skipping coffee or gum was still a challenge during that 4-hour window. 
This study excluded certain subcategories of GERD patients who have had the 
following diagnosis: asymptomatic ERD, hiatal hernia, Barrett's esophagus, and 
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adenocarcinoma patients.  GERD patients with active antacid prescriptions were also 
excluded.  Therefore the results of this study cannot be generalized to these populations, as 
well as pregnant women.    
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CHAPTER 2 
REVIEW OF LITERATURE 
Gastroesophageal Reflux Disease 
 Definitions and diagnoses.  There were various definitions of gastroesophageal 
reflux disease (GERD) among different countries because patients' clinical symptoms have 
wide ranges of manifestations.  This situation made clinical diagnosis and research purposes 
regarding GERD challenging.  In 1994, a classification of the esophagitis was proposed at 
the Los Angeles World Congress of Gastroenterology, and later this classification became 
known as the Los Angeles classification (Sami & Ragunath, 2013).   
The Los Angeles classification.  In 1996, David Armstrong and colleagues 
validated the Los Angeles classification through 59 endoscopists from different countries.  
The report examined the similarity of the participants’ diagnoses from endoscopic still 
images and video images.  Among all participants, the recognized complications had a more 
consistent recording; however, the problem of assessing “the circumferential extent and 
number of mucosal breaks” existed even among experienced endoscopists.  The researcher 
of the study thought the design of the evaluation worksheet might be at fault (Armstrong et 
al., 1996, pp. 89-90).  In 1999, Lars Lundell and colleagues did further validation of the Los 
Angeles classification.  At that time, the grading definition of esophagitis had changed  
(Table 1).  Forty-six endoscopists from different countries were recruited.  The mean K 
value of 0.4 was the result of the "circumferential extent" of esophagitis evaluation.  The 
closer the K value is to one, the more consistent the data is.  Lundell et al. pointed out that 
based on the Los Angeles classification, the diagnostic agreement of the esophagitis’ 
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circumferential extent in this study had a K value of o.4, which is only at an acceptable level.  
However, Lundell et al. also mentioned that the outcome of an alternative method had a 
mean K value of 0-0.15, which is considered unacceptable (p. 172).   
Table 1   
The Los Angeles classification of esophagitis1 
Grade A One (or more) mucosal break no longer than 5 mm, that does not extend 
between the tops of two mucosal folds 
Grade B One (or more) mucosal break more than 5 mm long that does not extend 
between the tops of two mucosal folds 
Grade C One (or more) mucosal break that is continuous between the tops of two or 
more mucosal folds but which involves less than 75% of the circumference 
Grade D One (or more) mucosal break which involves at least 75% of the oesophageal 
Circumference 
1 Lundell, Dent & Bennett et al., 1999, p. 173 
As the number of patients with symptoms of reflux grew in the clinical primary care 
setting, a need for a symptom-based definition for GERD was increasing.  The majority of 
patients who show symptoms of reflux do not go through further diagnostic tools, such as 
endoscopy.  They are either self-treated with over-the-counter antacid or prescribed proton-
pump inhibitors (PPIs) through their primary care providers.  These treatments are currently 
believed to be the most cost-effective or responsive for treating GERD symptoms regardless 
of their potential risk and side effects of long-term use (more details are in the treatment 
section below).  These patients are only referred to an endoscopist or gastroenterology 
specialist when their symptoms persist or relapse after the treatment (Zschau, Andrews & 
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Holloway et al., 2013).  The Los Angeles classification fell short of diagnosing this 
population of GERD patients, and defining the complication of vast symptoms associated 
with the disease.  Thus in 2007, Dr. Nimish Vakil and his colleagues developed the Montreal 
definition and classification of gastroesophageal reflux disease (pp. 1900, 1903 & 1914).   
The Montreal definition.  The final agreement of the Montreal definition was 
reached by a repeated anonymous voting process through a group of 44 experts from 18 
countries (Vakil, Zanten & Kahrilas et al., 2007).  Dr. Vakil and his group (2007) approached 
this definition differently from the Los Angeles classification because they wanted the 
Montreal definition to be "patient-centered" and "independent of endoscopic findings."  
This definition is patient-centered meaning each patient's well-being is considered when the 
symptoms become troublesome.  For example, having symptoms, such as heartburn or 
related pain, "on two or more days a week" is considered mild, but, if the patient's quality of 
life is seriously affected due to the symptoms, then the frequency and duration become less 
concerning, and the patient's symptoms are considered worse instead of mild.  They also 
emphasized that the definition is independent of endoscopic findings because many people 
might not undergo the endoscopy process or they used different diagnostic tools.  
Furthermore, the endoscopic finding may vary depending on the modernity of the diagnostic 
technology used, so the Montreal definition "is likely to endure despite changes in 
technology" (Vakil et al., 2007). 
The Montreal Definition of GERD, according to Dr. Vakil and his group's initiative 
result (2007), is "…a condition which develops when reflux of stomach contents causes 
troublesome symptoms and/or complications" (p. 1903).  Nonerosive reflux disease 
(NERD), which associates with the Los Angeles classification, is described as "esophageal 
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symptomatic syndromes" under the Montreal definition.  Erosive reflux disease (ERD), 
which based on patient's endoscopy findings according to the Los Angeles classification, 
would be described as "esophageal syndromes with esophageal injury."  Additionally "reflux 
esophagitis" is used when there is a sign of the esophageal injury, rather than erosive 
esophagitis.  The Montreal definition is able to include many more people with various 
GERD symptoms, and patients who used different diagnostic tests, besides endoscopy, such 
as various esophageal pH-monitoring tools, reflux monitoring, esophageal acid exposure 
recording, and the correlation between reflux episodes and symptom occurrences. 
Triggering factors.  GERD has vast varieties of manifestations with wide ranges of 
frequency and duration. The variable complications may affect the stomach, esophagus, 
throat, teeth, lungs, and ultimately the quality of life.  There is no clear-cut explanation for 
GERD symptoms and in current state, many underlying factors are needed further 
investigations or remain unclear.  Due to the safety concerns and side effects of PPIs long-
term use, the research trend has shifted GERD treatment focus from PPIs over the last few 
decades to understanding the underlying causes, hence readjusting and discovering better 
therapy options.   
Brain processing.  In 2010, a group of scholars in Shanghai, China compared the 
brain cerebral cortex reactions upon esophageal chemical stimulations among healthy 
volunteers and different types of GERD patients (Xu, Zheng & Zhao et al., 2010).  They 
concluded that when comparing how the brain receives and integrates sensations from 
esophageal stimulations, there are significant differences among healthy volunteers and 
within each GERD groups.  The result supports the proposition that brain sensory center 
  12 
strongly influences “esophageal visceral sensation” and thus, leads to different 
manifestations among GERD subgroups (Xu et al., 2010). 
Siwiec et al. in their 2015 article examined functional connectivity between 
esophageal acid stimulation and insular responding to the sensory information in GERD 
patients comparing to the healthy control.  The study tested the functional connectivity 
under 4 circumstances.  There was no difference between GERD patients and healthy 
subjects during pre-infusion phase.  Some regions between insula and thalamic had 
significantly higher activities in GERD patients during neutral saline, acid infusion and post-
infusion phases, however, some regions only showed significant reaction during acid 
infusion and post-infusion phase.  Interestingly, the right dorsal posterior insula and the right 
amygdala only showed significant connectivity during acid-infusion phase.  Furthermore, the 
connectivity between insular and hippocampus only showed significant difference during 
post-infusion phase.  The result of this study suggests that GERD patients might have 
abnormal highly active sensory afferents in the esophagus, "esophago-cortical neuraxis", and 
this could be an important underlying factor for NERD patients (Siwiec, Babaei, Kern, 
Samuel, Li & Shaker, 2015).        
Psychological factors.  Many studies have pointed out that psychological issues 
might be one of the essential factors in GERD.  Ronnie Fass and his colleagues did an 
experiment in 2008 on patients with typical GERD symptoms and healthy volunteers.  They 
introduced auditory stress to participants via a validated method by delivering “folk music in 
foreign language” to one ear and “heavy metal music” to the other ear at the same time (p. 
699).  The result demonstrated that stress can enhance GERD patients' perception to 
intraesophageal acid exposure, and worsen the symptoms.  The greater the emotional 
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response to the stressor, relates to a higher intensity of the intraesophageal acid perception.  
Fass et al. also points out that previous studies suggest that anxiety could also influence brain 
function on sensitization of GERD symptoms, such as heartburn, without the acid exposure 
to the esophagus (R. Fass, Naliboff & S. Fass et al., 2008).  Another research reported that a 
highly stressful life style for over a 6-month period would most likely increase heartburn 
symptom severities, but not the frequency, the following four months despite the actual 
reflux episodes might not match the upsurge (Naliboff, Mayer & Fass et al., 2004).  These 
results also support the proposal that stress enhances the sensory afferents of the esophagus. 
Transient lower esophageal sphincter relaxation (TLESR).  The term is defined 
as the relaxations of the lower esophageal sphincter when the action of swallowing is absent.  
Several studies described TLESR as the major cause to GERD (Schneider, Kuper, 
Konigsrainer & Brucher, 2009; Wu, Mui, Cheung, Chan & Sung, 2007; Pandolfino, Zhang, 
Ghosh, Han, Boniquit & Kahrilas, 2006).  However, the research studied frequency 
comparisons of TLESR among healthy individuals and GERD patients, the results were not 
consistent.  One research shows GERD patients have significant higher episodes of TLESR 
compared to healthy control group (Schneider et al., 2009), while another shows there is no 
consistent difference between two groups (Pandolfino et al., 2006).  However, Pandolfino et 
al. pointed out that there are more acid reflux occurrences accompanied TLESR in GERD 
population than healthy ones.  Therefore, targeting TLESR reduction in GERD patients has 
been a new strategy for pharmaceutical development. 
Pandolfino and his colleagues (2006) examined the process between the transient 
relaxation of the LES and the opening of the esophagogastric junction.  They found out that 
the mechanics, also involves "crural diaphragm inhibition, esophageal shortening, and a 
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positive pressure gradient between the stomach and the esophagogastric junction lumen" (p. 
1725).  The increased pressure from the stomach distention explains why often troublesome 
GERD symptoms occur after meals. 
In 2009, Schneider and his colleagues studied whether TLESR was the underlying 
cause of the connection between morbid obesity and GERD (p. 595).  In the article, they 
defined several types of TLESR.  Isolated TLESR takes place as single event.  Post-swallow 
TLESR occurs when the action of swallowing induces the LES relaxation.  There is also 
paired TLESR, which comes as double TLESR, and in this rare situation, the LES relaxes 
longer than other types of TLESRs.  The normal duration of the TLESR is 5 seconds.  The 
degree of the LES relaxation also classified TLESRs into complete and incomplete based on 
if the gastric baseline is reached.  Different types of TLESRs were compared among the 
groups, and with an upright posture, two hour after meal observed the highest frequency of 
TLESRs.  In the conclusion, GERD patients either with normal weight or obese GERD 
patients had significant higher postprandial TLESR frequency when compared to the control 
group (healthy individuals).  Regarding the TLESRs type, obese patients had majority 
complete isolated TLESRs and percentage is similar to the healthy control group.  
Incomplete TLESRs are significantly less in obese GERD group.  It is noteworthy that all 
the participants in the obese GERD group have had hiatal hernias.  This research also shows 
there is no association between TLESRs and LES pressure (Schneider, Kuper, Konigsrainer 
& Brucher, 2009).  As stated earlier, it is the positive gradient between stomach and the LES 
could trigger TLESR.  In a 2006 article, Crookes mentioned that typical western diet played 
an important role in production of TLESR, and carbonated beverages are included.  These 
beverages increase gastric distention and reduce LES pressure, thus lessen the threshold to 
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produce TLESR as well (Crookes, 2006).  As TLESR number creases, so as the possible 
episodes of reflux. 
Obesity.  The connection between obesity and GERD has been studied for decades, 
but the results are quite controversial.  A higher rate of hiatal hernias is noted in overweight 
and obese populations, which might due to a higher intra-abdominal pressure, and the 
association of the GERD symptoms, such as heartburn and acid regurgitation (Schneider et 
al., 2009).  Patients with hiatal hernia have compromised crural diaphragm contraction 
protection; hence acid reflux is more likely occurs.  Crookes pointed out in a 2006 article (p. 
465) that 228 symptomatic GERD patients sequentially selected in a foregut surgical 
practice; the mean BMI is 28 kg/m2.  According to the chart, patient number dramatically 
decreased when BMI is higher than 35 kg/m2 (Crookes, 2006).  However, a variable was not 
considered with this statement.  Patients with BMI higher than 35 kg/m2 might be advised 
to lose some weight before undergo a foregut surgery or patients in this population might 
have more complications with their health condition that prevent them from surgeries.   
Corley and colleagues did a cross-sectional study in San Francisco and Oakland, 
California in 2006 to evaluate the association among GERD symptoms, abdominal obesity, 
ethnicity and gender.  The sample size of this study is 80110 and the sample frame is the 
subjects who were interviewed in a cohort study, which was implemented between 1964 and 
1968.  Many gastroenterological risk factors have been studied through this cohort, such as 
gastric cancer, Helicobacter pylori, gastric lymphoma etc.  The result shows that there is an 
independent association between GERD symptoms and increasing abdominal diameters in 
white subjects, but this association is missing in black and Asian participants.  The 
association between GERD symptoms and BMI is also stronger in white populations than 
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black or Asian subjects.  Although men in this study have larger abdominal diameters in 
average, there is no association between GERD symptoms and gender (Corley, Kubo & 
Zhao, 2007). 
Pandolfino and colleagues analyzed gastro-esophageal pressure gradient and its 
relationship with obesity through high-resolution manometry in another article in 2006 (pp. 
639-649).  The results of higher pressure gradient between the stomach and the esophagus in 
obese subjects explains the likelihood of gastric juice flow into the esophagus, especially 
when the crural diaphragm moves down during inspiration, the stomach is compressed.  The 
gradient of this pressure has a positive correlation with increased BMI, and even stronger, 
when waist circumference is brought into the consideration (Pandolfino, EL-Serga, Zhang, 
Shah, Ghosh & Kahrilas, 2006). 
Interestingly, Dore and colleagues pointed out in a 2007 research article that atypical 
symptoms in GERD, such as "chest pain, sialorrhea, hoarseness, globus sensation, chronic 
coughing, episodic bronchospasm, hiccup, eructations, laryngitis, and pharyngitis," (p. 463) 
are not associated with BMI.  In fact, based on the study result (Table 2, p. 466), the 
frequency of these atypical symptoms dropped dramatically when participants' BMI were 
higher than 31 Kg/m2 (Dore, Pedroni & Pes et al., 2007). 
Smoking.  Several studies have shown smoking has adverse effect to GERD 
symptoms.  The reasons are the following: (1) Smoking reduces LES pressure, which 
increased the chance of gastric acid reflux to the esophagus (Stanciu & Bennett, 1972).  (2) 
Smoking reduces the salivary gland secretion.  There is a large amount of bicarbonate ion in 
the saliva works as buffer to neutralize the acid in the mouth and the esophagus.  Reduced 
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saliva drastically reduces the esophagus' acid buffering mechanism through chemical 
reactions (Ness-Jensen, Lindam, Lagergren & Hveem, 2014).  (3) While smoking, the 
inspiration phase of breathing brought in a large amount of nicotine, and Miller et al. 
pointed out that enhancing nicotinic receptors can mediate relaxations in gastroesophageal 
muscle, which would decrease the anti-reflux barrier between the stomach and the 
esophagus (Miller, vegesna, Braverman, Barbe & Ruggieri Sr., 2014).  (4) The stomach 
pressure increased during the inspiration period, thus the gastro-esophageal pressure 
gradient increased.  Then gastric acid is driven to flow back into the esophagus.  (5) A long-
term usage of nicotine would damage the epithelium and mucosa (Nakajima, Nagahara & 
Kurosawa et al., 2011).  This condition allows more chemical passing through the esophageal 
wall and enter the intra-cellular space, thus enhances the stimulation and reaction of the 
neural system.      
A prospective study in 2011 by Nakajima et al., support the proclamation that quit 
smoking can not only alleviate GERD symptoms but also improve the quality of life 
(Nakajima et al., 2011).  Contradictorily, a cohort study in 2014 by Ness-Jensen et al., shows 
the result that quitting smoke only improves GERD disease in the individual who is not 
overweight or obese; takes anti-reflux medication weekly; and has severe GERD symptoms 
(Ness-Jensen et al., 2014). 
Diet.  A majority of GERD symptoms, especially heartburn and acid regurgitation, 
happen after a meal.  Heartburn, based on the Montreal definition, is "a burning sensation in 
the retrosternal area (behind the breastbone)" (Vakil et al., 2007).  Many studies assessing 
heartburn severity or an item's efficacy in heartburn alleviation require a reliable method to 
induce consistent heartburn sensation in the participants.   
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In 1998, Rodriguez and colleagues tested three different meal compositions based on 
their calories, osmolality, pH, volume and fat contents (p. 487).  They evaluated each meal's 
heartburn-inducing capability; on-set timing of the symptoms; the number of reflux 
episodes; each participant's gastric pH; and the duration of symptoms.  The total recording 
time of the symptoms was 180 minutes since starting of the meal.  All three meals induced 
heartburn among the participants.  Wendy's Chili and red wine induced the highest incidents 
of heartburn among the participants during the first 45 minutes of the trial, comparing to 
McDonald's hamburger with chocolate shake, or McDonald's sausage biscuit with chocolate 
milk (p. 488).  Tomatoes, caffeine, peppermint, onions, chocolate, orange juice, and 
capsaicin are considered as irritating ingredients that might cause heartburn symptoms in 
GERD (Rodriguez, Miner, Robinson, Greenwood, Maton & Pappa, 1998). 
Gastric distention.  Besides the heartburn-causing ingredients, gastric distention 
can also induce heartburn when a big meal expands the stomach to a certain degree.  In 
1985, Holloway and colleagues examined how gastric distention affects LES pressure in 
healthy volunteers and GERD patients (p. 779).  LES pressure drops during gastric 
distention, and TLESR occurs.  Sometimes the incidence is also followed by the opening of 
the esophagogastric junction, which allows the contents of the stomach to flow back to the 
esophagus, thus leading to reflux.  Holloway et al. inserted a balloon in each participant's 
stomach and inflated it to 250, 500, and 750 ml for the placebo group and 250, and 500 ml 
for the reflux patients.   They concluded that the rate of TLESR was the major factor that 
induced the postprandial esophageal reflux rather than the dropping of the LES pressure 
because there were no significant changes in LES pressure between the placebo and the 
experimental groups.  Even though the placebo group and GERD patients had similar rate 
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of TLESR, GERD patients had higher percentage of "complete relaxations."  According to 
the chart, when the balloon was inflated to the volume of 500 ml in the experimental group, 
the number of TLESR increased one and half fold comparing to the volume of 250 ml 
(Holloway, Hongo, Berger & McCallum, 1985). 
Alcohol.  In 1997, Teyssen et al., compared alcoholic beverages made from different 
processes, and they discovered that the process of the alcohol production is a key variable, 
which influences the capacity of the alcohol, stimulating gastric acid output and releasing 
hormone gastrin in the stomach.  When drinking the type of alcohol, which fermentation is 
the only process involved in the production, the output of gastric acid and releasing of the 
gastrin is significantly increased.  These types of alcohol are "beer, wine, champagne, martini, 
and sherry" (Teyssen, Lenzing, Gonzalez-Calero, Korn, Riepl & Singer, 1997, p. 49).  The 
process of distillation significantly decreases the influence of the alcohol has on the gastric 
acid and gastrin.  Teyssen et al. prior to this research did a study in stimulants of gastric acid 
in beer.  The result showed that the step of adding yeast during the production was crucial 
for the trigger of acid secretion because the byproduct, fermented glucose, from this step 
was the most powerful stimulant (Teyssen et al., 1997).   
  This condition might be explained that one of the main functions of the stomach 
acid is to protect our digestive system by killing the potential harmful microbe with its strong 
acid.  A product made from fermentation process without distillation could contain a large 
amount of microbe, which stimulates the gastric acid secretion.  Coincidentally, vinegar 
produced without the process of distillation consists of many similar characters that a 
fermented alcohol has, except the muscle relaxing effect.  Rodriguez et al. pointed out the 
conflict reports on alcohol consumption and its effect on resting LES pressure.  Both 
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increasing and decreasing effects on resting LES pressure were noted in different research 
studies (Rodriguez et al., 1998).  Alcohol's ability to relax muscle contractions is commonly 
known, yet the gastric acid stimulating ability might connect the role of acid and its reaction 
with the LES structure, thus explains the result of increasing resting LES pressure. 
Acid pocket.  The idea that acid reflux mostly happens after a meal seems 
contradictory because one would think that the food ingested during the meal would buffer 
the acid in the stomach (Rohof, Bennink, Smout, Thomas & Boeckxstaens, 2013).  Indeed, 
in a 2001 study, which recruited dyspeptic patients with negative endoscopy results, Fletcher 
et al. pointed out that median fasting gastric juice pH was 1.3 (range 1.0-1.9), and the meal-
related mean peak intragastric pH was 5.2 (range, 2.7-7.2).  However, the median of the 
minimum gastroesophageal reflux content pH was 2.5 (range, 1.1-3.4) at fasting state and 3.0 
(range, 2.1-3.5) postprandial.  The median gastric minimum pH one minute before the reflux 
episode was 3.2 (range, 1.4-5.3), which had a much wider range of pH than the reflux 
content in both fasting and postprandial states.  Though not statistical significant, it 
demonstrated that the acidity of gastric juice was not the main underlying cause of 
gastroesophageal reflux. 
Fletcher et al. revealed that the body region of the stomach has a higher pH value 
than the antrum region postprandial.  The cardia region of the stomach which is closest to 
the esophagus had many unbuffered acid pockets that did not get mixed with ingested food 
(Fletcher, Wirz, Young, Vallance & McColl, 2001).  These acid pockets might explain the 
slightly more acidic esophageal reflux than the stomach content postprandial (Fletcher et al., 
2001).   Furthermore, this condition might explain the physiological mechanics of the acid 
sensitive nerve cells in stomach cardia region that helps the contraction of the LES. 
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Subcategories of GERD.  Based on the pathogenesis of the disease and its 
complications, GERD can generally be categorized into the following subgroups. 
Functional heartburns (FH).  This group of patients previously was combined 
with NERD and "acid sensitive esophagus" since all three groups share similar 
characteristics of the symptoms, such as no evidence of esophageal mucosal breakages from 
endoscopy results and a hyper-sensitive esophagus.  However, some significant difference 
among these three groups has led experts in the field to re-categorized these patients so as to 
better diagnose each individual accordingly.  Hence a more suitable treatment can be applied 
to each group of patients (Zerbib, Varannes, Simon & Galmiche, 2012; Savarino, Zentilin & 
Tutuian et al., 2012). 
Compared with negative endoscopy and biopsies findings, and a normal acid 
esophageal exposure, the key distinction criterion to the functional heartburn group is that 
their symptoms have a negative association with the acid-reflux episodes.  This is the only 
subcategory under GERD where the patients exhibit 100% reflux-like symptoms.  All other 
GERD subgroups with "morphological changes" have some patients who are asymptomatic 
(Ronkainen & Agreus, 2013, p. 326).  Yet, the one distinguish factor between this group of 
patients and healthy population is the reflux-like symptoms that are not related to acid reflux 
episodes.  In 2012, Edoardo Savarino and his colleagues did a study to differentiate NERD 
from FH by impedance-pH monitoring.  The result of the pH-monitoring shows no 
difference between FH patients and healthy volunteers, and this finding might explain the 
particularly high refractory rate of PPI treatment in FH group (p. 165).  There are less than 
10% of patients in the gastroenterologists' offices belonging to this group.  However, the 
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estimated percentage might be higher in the primary care clinical offices (Galmiche, Clouse 
& Balint et al., 2006).  
The reasons underlying the symptomatic presentations in the FH group are still 
largely unidentified.  However, many studies support the fact that psychosocial factors are 
especially more important in this group than other variables.  Anxiety disorders, depression, 
sleep deprivation, somatization disorder, and poor social support are reported more 
frequently in this group.  It is also noteworthy to point out that female patients form the 
majority of this group. 
 The treatment plan for FH should base on each patient's condition, and aggressive 
tests need to be prescribed cautiously.  Since FH generally do not respond to PPI treatments, 
high dosage of acid-suppressant therapy should be avoided.  After all, the heartburn and pain 
symptoms that these patients suffer from are not associated with acid reflux in the first 
place.  Pain management approaches currently are the most recommended by the experts 
even though there are not many clinical trails exist to validate these approaches (Zerbib et 
al., 2012).  
Non-erosive reflux disease (NERD).  The definition of this group is mainly based 
on patients' negative endoscopy results that show no signs of breakage or injury of the 
esophageal wall.  However, biopsy results might show slightly cells type change, such as 
"lymphocytic infiltration, papillary elongation, basal cell hyperplasia and dilated intracellular 
spaces" (Ronkainen et al., 2013, p. 326) on the esophageal wall due to the abnormal 
esophageal acid exposure.    Many epidemiology and review reports indicated that 50% up to 
75% of GERD population has a negative endoscopy result (Savarino et al., 2012; Hartono, 
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Qua & Goh et al., 2011; Goh, 2004).  Under broad considerations, these patients would be 
considered as NERD until more detailed symptoms are investigated.  Then FH might be the 
diagnosis instead of NERD.  Patients in this group have a little better responsive rate to PPI 
treatments than the ones in FH group.  Though in general, this group shares the fame of 
refractory toward PPI treatment with FH group. 
NERD patients are considered having hypersensitive esophagus.  Hartono et al. in a 
2010 experiment compared esophageal sensitivity of different GERD groups.  Based on the 
patients' endoscopy results, they were divided into NERD and ERD groups.  Then 
according to the presentation of the symptoms, ERD is further divided into asymptomatic 
and symptomatic group.  Patients who have experienced reflux symptoms more than once 
per week for the preceding 3 months were recruited.  The result shows that NERD patients 
not only feel the symptoms during the acid perfusion period, but also when saline was 
infused (Hartono et al., 2011).  Therefore, one can expect low intraesophageal pH value is 
not the only issue causes GERD symptoms.  Conflictingly, Fletcher et al. mentioned that 
during esophageal acid-perfusion tests, an average threshold for symptoms is pH 2.5.  When 
pH is above 2.5, symptoms and "acid-induced salivation" are rarely noticed (Fletcher et al., 
2001).  Though in Fletcher et al. study, on-set of symptoms were only measured when 
intraesophageal pH was lower than 4, so the non-acidic reflux was not recorded in the study.  
Based on Hartono et al. study, NERD patients might be suffering from both acidic and non-
acidic reflux.  The esophageal wall of the NERD patients show much less damages from 
acid when compared with ERD groups, the fact might indicate that reflux in NERD group 
are more prevalent in non-acidic reflux than the acid ones.  There are many acid infusion 
experiments studied how the esophagus reacted to the acid when it was introduced through 
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the tube, but currently there is no study examined the esophageal reaction when the acid is 
ingested as food.   
Erosive reflux disease (ERD).  ERD is defined as positive-endoscopy result with 
esophageal mucosa breakage, and the diagnoses based on the Los Angeles classification can 
be categorized into grade A, B, C and D (Table 1).  The term erosive esophagitis is 
sometimes used as well.  In this category, based on the symptoms presentation, it is further 
divided into symptomatic and asymptomatic.  In a 2010 study, Hartono et al. demonstrated 
that symptomatic ERD group responded to acid reflux more significantly than the healthy 
volunteers, but saline infusion did not induce GERD symptoms in this group as it did in 
NERD group.  In asymptomatic ERD group, both saline and acid infusion did not induce 
symptoms indicating this group has a hyposensitive esophagus (Hartono et al., 2011). 
Generally ERD is more prevalent in Western world (10-20%).  Recently many 
countries in Asia have research related to the increasing prevalence of ERD in Japan, Taiwan 
and Korea.  In 2012, Ou and colleagues did a prevalence study in Taiwan, according to the 
reports, in 1995 the prevalence of ERD was 5%, and then the rate changed from 14.5% in 
2000 to 23.5% in 2007.  The majority of the ERD patients in this study result were grade A 
(71.6%), and there were very few grade C and none in grade D.  The study also identified 
that "male sex, smoking, obesity, and hiatus hernia" were risk factors of ERD (Ou, Tu & 
Hsu et al., 2012, p.63).   
Schneider et al. in their 2009 article related to TLESRs and morbid obesity, an 
interesting result was observed.  In the GERD group with normal weight participants (BMI 
= 27 kg/m2), its TLESR frequency was a lot higher in recumbent position compared to the 
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other three groups (healthy control, obese GERD and diffuse esophagus spasm) in the study 
(Schneider et al., 2009).  Ribolsi et al. did an esophageal peristalsis study (2014), and 
observed that in the supine position, comparing to NERD, ERD needs significant longer 
time to clear the bolus and has a significant higher percentage of acid exposure time.  
According to the result, they indicated that this finding might explain the underlying cause 
for the erosion development and esophageal mucosal damages in ERD patients (Ribolsi, 
Balestrieri, Emerenziani, Guarino & Cicala, 2013).  
As one expects, a more advanced endoscopic diagnostic tool would improve the 
detection of the breakage on the esophageal wall.  Interestingly, Amano et al., did a study in 
2008 in Japan compared conventional and magnifying endoscopy, and revealed a different 
answer.  The K value was .76 between two methods, which indicated both methods had 
good agreement on the diagnoses despite the technology gap (Amano, Yamashita & 
Koshino et al., 2008). 
Surprisingly, a study Jung et al. did in Republic of Korea in 2013, revealed that non-
vegetarianism diet as one of the risk factor, which associates with ERD, when compared it 
with Buddhist priests group (p = .03).  This study recruited 148 participants (79 male, 69 
female) for each group.  In Asian Buddhist priests, many people who follow the vegetarian 
diet, besides meat, they do not eat onion, scallion, leek, or garlic because these plant-based 
food was believed to disturb the calmness of one's mind.  Furthermore, many of them 
follow a life style of no drinking and smoking.  As previously discussed in the triggering 
factors section, onions, sausage, alcohol and smoking are the items might induce heartburn, 
though the Buddhist vegetarian diet's protective effect against ERD remained unclear.  
Compared the male participants' biomedical data of the Buddhist priests with the general 
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population in the study, unexpectedly, Buddhist priests group had statistically significant 
higher number in metabolic syndrome, weight, BMI, waist circumference, total cholesterol, 
total adipose tissue area (both visceral and subcutaneous), and significantly lower HDL 
(p ˂ .05).  However, despite all the biomedical factors, the reflux esophagitis rate was still 
significantly lower in the Buddhist priests group (Jung, Kang & Hahn et al., 2013).  Oddly, 
the description of the study result conflicted with the data in its Table 1, which it referred to, 
and stated there was no statistically significant difference between the two study-groups on 
the factors previously mentioned. 
In 2004, El-Serag et al. did a cross-sectional study of the employees at a VA medical 
center in Houston.  The aim of this study was observing how races played a factor between 
GERD symptoms and ERD.  The racial distribution in this study was 43% black, 34% 
white, 23% others ("8% Hispanic, 11% Asian, 1% Native American, and 3% others") (p. 
1694).  The result revealed white population is more accessible to ERD than black (El-Serag, 
Petersen & Carter et al., 2004).  In 2005, Japan did the first national epidemiology survey 
related to heartburn and ERD, and out of 3608 people 602 patients reported ERD as grade 
A-D (16.7%), and 210 patients out of these 602 patients were asymptomatic (34.9%) (Ohara, 
Kouzu, Kawano & Kusano, 2005). 
ERD is thought to be a progressive disease toward Barrett's esophagus, and 
eventually might lead to esophageal adenocarcinoma, so long-term lasting GERD symptoms 
are a warning sign of a more serious disease.  Erichsen et al. did a cohort study using the data 
collected from 1996 to 2008 in Denmark, and concluded that ERD patients' absolute risk of 
developing esophageal adenocarcinoma after 10 years was 0.24%.  The inflammation of the 
esophageal wall might be the source of the origin (Erichsen, Robertson & Farkas et al., 
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2012).   The problem is that asymptomatic patients normally do not have a sense how 
serious their conditions are until endoscopy is performed.  Jung et al. mentioned that 
esophagogastro-duodenoscopy is an annual or biannual procedure in Korea as a screening 
tool for gastric cancer (Jung et al., 2013).  
Barrett’s esophagus(BE).  While FH and NERD groups are mostly female 
patients, males are more prevalent in ERD, BE and esophageal adenocarcinoma groups.  
After a long period of acidic reflux damaging the esophageal mucosal wall, metaplasia of the 
esophageal stratified squamous epithelium occurs, and turns those acid-sensitive cells into 
the intestinal columnar epithelium, which has a better tolerance to acid.  Therefore, BE 
patients are less sensitive to GERD symptoms, such as heartburn.  The diagnosis of BE is 
made when the esophagus has some pink lining at its distal end under endoscopy and biopsy 
result of the pink layers shows intestinal metaplasia (Cameron, 2002; Modiano & Gerson, 
2009).  Cameron pointed out that reflux symptoms are 2.2 to 4.8 times higher in the 
population who has first degree relatives with BE.  Age is one of the risk factors of BE.  For 
people 60 years and older, who have a routine endoscopic check up, 1% of them are 
diagnosed with BE.  Male patient's prevalence is twice that of female's (Cameron, 2002).   
Esophageal adenocarcinoma (EAC).  Currently EAC has grabbed a great deal of 
attention in the research because in 25 years (from 1975 to 2001) the rate of incidence has 
increased six folds, and mainly in the U.S. and the Western world.  EAC is also the major 
type of histologic esophageal cancer in the United States.  The long-term survival rate of this 
cancer is low, but in the last 30 years the rate has been improved.  Besides the advanced 
surgical technology and therapy care, early detection should be considered as a goal for the 
clinical primary care setting (Modiano et al., 2009; Hur, Miller & Kong et al., 2013). 
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Upper Gastrointestinal Tract Physiology 
Stomach.  Gastric acid juice used to take the main blame for the symptoms of 
GERD.  The sale records of over-the counter antacid medication indicates that this notion 
still occupies a big part of the market.  The strategy of the past was to increase the pH of the 
total stomach acid, so that even if it got into the esophagus, there would be no discomfort or 
damage to the esophageal wall.  The main component of antacid is Calcium Carbonate 
(CaCO3).  Similarly saliva has a large amount of Carbonate in its content as well.  However, 
instead of neutralize the pH in the esophagus; the aim of antacids is to neutralize the acid in 
the whole stomach. 
Ayazi et al. explored the relationship between resting gastric pH and esophageal acid 
exposure in 2008 with 54 healthy volunteers and 1582 GERD patients' pH records from a 
lab.  Normal gastric pH was set by healthy volunteers, and the median was 1.5 (range 1.1-1.9) 
with 5th percentile was 0.3 and 95th percentile was 2.9.  The GERD patients' records were 
divided into normal gastric pH group and hypochlorhydria group ("gastric pH above the 95th 
percentile of normal"; pH > 2.9) (p. 1970).  Normal gastric pH GERD group generally had a 
higher rate of gastroesophageal reflux episodes.  Except during the supine positon, 
hypochlorhydria group had more reflux, though it is not statistic significant.  It is also 
noteworthy that in this study, patients' gastric pH records' distribution was bimodal.  The 
median gastric pH was 1.7 in normal gastric pH GERD group, and it was slightly higher 
than healthy volunteers' median pH value of 1.5.  This finding indicates that too much of 
gastric acid is not the main cause of GERD symptoms (Ayazi, Leers & Oezcelik et al., 2009). 
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The rat gastric stimulating studies have shown that vagal and spinal sensory neurons 
respond to unpleasant gastric distention or acid stimulation significantly different.  These 
studies suggest that even though vagal and spinal afferents are both sending the sensory 
information to the brain, they have distinct functions.  Sakurai et al. in their 2008 article 
mentioned that in the stomach, vagal afferents are mostly sensory neurons that carry 
information from noxious chemical stimulation, and spinal afferents are in charged of the 
perception of harmful mechanical stimuli (Sakurai, Obata & Ozaki et al., 2008; Sugiura, 
Dang & Lamb et al., 2005).  Previously mentioned in the triggering factors section that 
unbuffered acid pockets in the stomach after a meal tend to locate in cardia region of the 
stomach, and these acid pockets contain concentrated proton, which might influence gastric 
vagal afferent to generate action potentials.   
Lower esophageal sphincter (LES).  LES is a very important structure between 
the esophagus and the stomach.  With the help of the crural diaphragm to give the pressure 
on the exterior lining of the LES, a barrier is created to prevent the contents of the stomach 
to reflux into the esophagus.   
In human, and most of the other animals, LES is not visible.  Therefore, when 
conducting a research related to measuring LES pressure or TLESR, the definition of the 
LES has to be stated to avoid confusion.  The term the esophagogastric junction is also 
often used.  The narrowing of the esophagus where the angle of His locates is not how LES 
is defined.  However, the sharp angle created a flap, which also helps on the mission of 
preventing reflux.  Most of research related to GERD would define the location of the LES 
by manometry.  It is an area, which has a higher pressure compared to the surrounding 
(Miller, Vegesna & Brasseur et al., 2011).     
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The muscle structure of the LES is quite complicated, and it has intrinsic smooth 
muscle and extrinsic skeleton muscle parts.  One of the intrinsic parts is the flap created by 
the angle of His on the lower left side of the esophagogastric junction.  It is composed of 
stomach muscle fibers, and sometimes this part is also referred to as "upper gastric 
sphincter."  This part of the stomach muscle increases its contractility as a respond to 
cholinergic stimulation.  During postprandial, both cholinergic antagonism and stimulation 
work on the stomach.  Cholinergic receptors are important to gallbladder emptying, which 
happens when stomach is about to emptying its contents.  This part of the LES contracts 
not only during the period of postprandial but also when the stomach is emptying (Parkman, 
Trate, Knight, Brown, Maurer & Fisher, 1999; Miller et al., 2011). 
The other intrinsic part of the LES is the distal part of the esophagus.  This area is 
overlapping with the cardia part of the stomach, but it is made up of the esophageal semi-
circular smooth muscle.  The contraction of this structure is coordinated with the third 
component of the LES, the extrinsic skeleton muscle of the crural diaphragm.  The hiatal 
hernia occurs when these two parts misaligned, and considerably decreased the LES anti-
reflux ability.       
Esophagus.  Esophagus is a 20 to 22 cm tubular structure connecting the pharynx 
and the stomach and constructed by both striated skeletal muscle (upper esophagus) and 
smooth muscle (lower esophagus).  Esophageal peristalsis is managed by inner layer of 
circular muscle and outer longitudinal muscle layer with complicated nervous system, include 
spinal (sympathetic) and vagal (parasympathetic) pathways.  The distinguish function of 
different sensory afferents in the stomach carried into the esophagus.  The action of 
swallowing stimulates the vagal motor neurons in the striated muscle with a top to bottom 
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sequence in a combination of inhibition and excitation mode.  This movement is called 
primarily peristalsis, and it is controlled by central nervous system (CNS).  Although the 
peristalsis wave continues in the smooth muscle part of the esophagus, the peripheral 
nervous system joins the control of the contractions.  The role of CNS in this part of the 
esophagus might involve acetylcholine receptors.  Smooth muscle in the esophagus is not 
necessary to contract in a sequacious manner and circular contraction can be generated 
without simultaneously top to bottom direction (Park & Conklin, 1999; Dodds, Christensen, 
Dent, Wood & Arndorfer, 1978).   
Previous research has pointed out that GERD patients frequently have the 
conditions of delayed bolus transit and trouble to clear the reflux from the stomach, 
especially when they are in the supine position.  With a newer technology, high-resolution 
manometry, Ribolsi et al. examined the length of broken wave and weak peristalsis in GERD 
patients in their 2013 study.  If wave break was more than 5 cm in the 20 mm-Hg isobaric 
contour in more than 20% of swallows or 2 to 5 cm in more than 30% of swallows, then the 
patient had a weak peristalsis.  The result found that the pathological number of large breaks 
(>5 cm) in the peristalsis wave was associated with a statistical significant longer time 
required for bolus transit and reflux clearance when the patients were in the supine position.  
These patients also had a longer acid exposure time in the distal esophagus (Ribolsi et al., 
2013).  In 2012, Tsutsui et al. also did a study in Japan examined globus sensation with a 
subtype of GERD - laryngopharyngeal reflux disease (LPRD).  Patients with LPRD feel as if 
a lump in their throats and previous research has shown this sensation is associated with 
heartburn and regurgitation.  This study found association among old age, male gender, less 
serious reflux-related symptoms and resistance to treatment with PPI.  Also, PPI-resistant 
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LPRD patients have significant less percentage of peristaltic contractions and complete 
bolus transit when comparing to the healthy control group.  It is noteworthy that the mean 
BMI of the participants in this study was around 20 kg/m2 (Tsutsui, Manabe & Uno et al., 
2012).   
The interior wall of the esophagus has several layers of protection to prevent acid 
damage from the stomach reflux.  A watery layer full of bicarbonate covered the lumen of 
the esophagus is the first line of defense.  Stratified squamous epithelium is the 2nd line of 
protection.  It has been suggested that the lose integrity of this layer might be the underlying 
reason for neutral-reflux to cause heartburn because the reflux substance could enter the 
connective tissue below through the gaps among epithelium cells.  Metaplasia of the 
epithelium layer due to prolonged acid exposure has been discussed in the Barrett's 
esophagus section.   
The layer of connective tissue below is called lamina propria.  This is where 
esophageal cardiac glands locate.  Hanada et al. conducted a study in Japan in 2014 and they 
suggested that having esophageal cardiac glands (ECG) was an independent protective factor 
for reflux esophagitis, but GERD symptoms were not inhibited by the ECG (Hanada, 
Adachi & Mishiro et al., 2014).  ECG secretes acid-neutralize mucus, however the 
prevalence of this gland is only 50% in the general US population and its existence is 
controversial (Huang, 2011).  While Huang concluded that cardiac gland in the proximal 
stomach to be congenital, in Hanada et al. study, however, there was only 13.4% of 
participants had ECG.  Due to the cardiac gland in the stomach mucosa locates around 
esophagogastric junction where LES is, it is called ECG when it locates in the esophageal 
mucosa.  In Hanada et al. study, they detected the presence of ECG by the endoscopy 
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procedure and defined the yellowish lesion in the distal part of the esophagus as ECG.  They 
pointed out the yellowish elevated areas commonly locate at left-posterior wall of the 
esophagus while most of the GERD related erosion or esophagitis happens on the opposite 
side of the esophagus wall.  Furthermore, the ECG in this study, are more prominent in 
patients with H. pylori infections, and participants who have more serious gastric mucosal 
atrophy (Hanada et al., 2014).  It might be the H. pylori infection reduces gastric acid 
secretion, and esophagitis, which is damage of the esophageal wall by gastric acid, thus 
reduces as well (Koike, Ohara & Sekine et al., 2001).  More research is needed to investigate 
the association between the ECG and its protective factor for esophagitis. 
Although TLESR is believed to be one of the main causes of GERD symptoms, the 
occurrence of TLESR sometimes are followed by esophageal motor responses.  These 
esophageal motor responses also noticed during the acid perfusion tests in the esophagus.  
Sifrim et al. did a study in 1996 to investigate the association of TLESR and esophageal 
motor response in healthy volunteers.  The result shows TLESR does not inhibit esophageal 
body contraction.  Furthermore, introduction of acid without expanding the lower 
esophagus, on the other hand, increased the esophageal muscle contractility (Sifrim, Janssens 
& Vantrappen, 1996).   
In 1978, Dodds et al. did a study in the opossum to investigate esophageal 
contractions induced by vagal nerve.  The result showing that the esophageal smooth muscle 
contraction that induced by vagal stimulation maybe have a similar function of peristalsis, 
which is clearing the esophagus and pushing the contents toward the stomach.  Most of the 
stimulations were focused at two-thirds of distal part of the opossum esophagus through 
electric frequency, bubble-free water, stroking with a cotton swab (cervical area) and 
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different drugs.  They concluded that vagal pathway efferent mediated three types of smooth 
muscle contractions in the opossum esophagus.  These three types contractions are A and B 
waves of circular contraction and longitudinal contraction (Dodds et al., 1978; Schneider, 
Kuper, Konigsrainer & Brucher, 2008).  Several previous articles have shown that the 
afferent nervous system in the esophagus and the stomach involved both vagal and spinal 
pathways.  Vagal afferents majority carries the signal from chemonociceptor and spinal 
afferents carry the signals of mechanical stimuli, such as the distention or stretch of the 
esophagus or the stomach (Sakurai et al., 2008; Sugiura et al., 2005). 
GERD Treatment 
 There are many kinds of medicine that is used to raise stomach pH to help relieve 
discomfort symptoms of GERD because over the past few decades gastric acid has been 
considered the main source of the problem.  Proton-pump inhibitor has been a very popular 
treatment choice for GERD over the past few decades.  Previous research mentioned 
majority of PPI was prescribe in primary care setting for patients exhibited GERD 
symptoms before further tests, such as endoscopy, even though patients might not respond 
to PPIs adequately (Zschau, Andrews & Holloway et al., 2013).   Dore et al. suggested that 
for patients exhibited atypical symptoms of GERD, prescribing PPI before referring them to 
specialist was cost effective therapy (2007).  PPI suppresses gastric acid secretion by blocking 
the H+/K+ ATPase, which is the channel on the parietal cells to bring H+ into gastric gland 
lumen.  Cimitidine is another acid suppressant used to reduce gastric acid secretion.  It 
prevents histamine stimulates parietal cells secreting HCl by blocking its binding site - H2 
receptors.  Over-the-counter antacid, such as the one was used for the antacid trial of this 
study, contains a great deal of alkaline ions, such as calcium carbonate.  When it is ingested 
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and arrives the stomach, the release of abundant CO3- neutralizing the gastric acid directly in 
the stomach lumen.  Feldman pointed out that calcium carbonate although works rapidly, 
the effect duration was only 60 minutes (Feldman, 1996).  According to the result of the 
current study, calcium carbonate antacid seem has improved its effectiveness since 1996 
because during the antacid trial, it suppressed heartburn symptoms during the whole 120 
minutes testing time in the antacid responder group.  
Dramatic changing the pH in the stomach causes many side effects that were 
mentioned in the introduction.  Therefore recent research has published alternatives that 
might help GERD patients relieve their discomfort without targeting the gastric acid.  
Collings et al. showed that calcium carbonate gum (1000 mg CaCO3 or 600 mg CaCO3 ), 
which only neutralized the pH in the esophagus, significantly relieved heartburn sensation 
after a meal compared to the placebo treatment in a cross-over design study.  It is note 
worthy that traditional chewable antacid was used as a positive control, and during all four 
trials, the mean gastric pH was never higher than 3.0.  Additionally, the lower dose gum 
worked as well as the high dose one.  By comparing to the placebo trial, two antacid gum 
trials had longer lasting heartburn relive than the traditional chewing antacid (2002).    
In 2013, Brown et al. did another cross-over design study investigating the 
effectiveness of a novel gum, GutsyGumtm, to alleviate heartburn after a meal.  The gum 
contains 500 mg calcium carbonate, "with a proprietary blend of licorice extract, papain, and 
apple cider vinegar (GiGs®)."(p.1)  Result showed a significant decrease on heartburn and 
acid reflux when compared to the placebo.  However, the symptoms of nausea and belching 
did not show a significant decrease compared to the placebo, while the symptom of pain had 
a tendency to decrease although not statistically significant (p= .081) (Brown, Sam, Green & 
  36 
Wood, 2014).  Rohof et al. did a study with patients had symptomatic GERD and large 
hiatal hernias using aliginates to target acid pockets near the esophagogastric junction after a 
meal.  Alginates are natural polysaccharide polymers that react to gastric acid and become 
gel.  The result showed during the 2-hour recording time, alginates formed gel successfully 
targeted acid pockets near the esophagogastric junction and had more than 75% reduction of 
acid reflux episode and an hour delayed reflux compared to the 15 minutes of the antacid 
group (Rohof, Bennink, Smout, Thomas & Boeckxstaens, 2013). 
Fundoplication is a surgical option for GERD since 1956.  The procedure sews the 
fundus of the stomach around the LES area.  However, there are many side effects related to 
this surgery, such as increased bloating and flatulence because the patient could not belch 
easily.  A modern surgical option is magnetic sphincter augmentation, which is a ring-like 
metal structure helps LES work as a barrier.  Schwameis et al. did an assessment on the 
efficacy, safety and feasibility of this option, laparoscopic sphincter augmentation.  They 
concluded that this procedure was minimally invasive, feasible, and safe.  Especially when 
compared to the fundoplication, this procedure is reversible.  After 4-weeks of 
implementation, the result showed patients' GERD-related life quality increased significantly; 
PPI need reduced; and effective alleviation of GERD related symptoms.  However, the 
concern of the metallic ring might prevent patients from magnetic resonance image test is 
need to be solved (Schwameis K., Schwameis M. & Zorner et al., 2014).       
Vinegar 
 There has been increasing number of research related to vinegar since 1990s, 
especially after year 2000 and hit its peak in 2011.  Johnston et al. pointed out vinegar has 
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been used for variety function since c. 5000BC.  For example, food preservative, managing 
wounds, dissolving boulders, hand washing with sulfur to prevent infection, treating varies 
ailment, and antiglycemic agent constitute the history of the vinegar usages (Johnston & 
Gaas, 2006).  Mitrou et al. did a study in subjects with impaired glucose tolerance.  They 
concluded that drinking vinegar before a mixed meal (glycemic index 52, Carbohydrates < 
75g, dietary fibres 3.3g), would increase skeletal muscle (forearm) blood flow.  The benefit of 
this result was increased glucose uptake, improved insulin sensitivity, and lowered 
triglycerides in the blood after a meal (Mitrou, Petsiou & Papakonstantinou et al., 2015).  
Brown et al. mentioned that apple cider vinegar has many anecdotal reports on its 
helpfulness in GERD symptoms, and the explanation might be the shock of acid would 
close LES and hence, prevent the reflux (Brown et al., 2014).  Apple cider vinegar was one 
of the ingredients in the antacid chewing gum in their study. 
 The production of vinegar involved raw materials that have starch or sugar, and the 
fermentation process of transforming ethanol into acetic acid (Budak, Aykin, Seydim, 
Greene & Guzel-Seydim, 2014).  Aykin et al. explained in their article that mother of vinegar 
is a think and hard layer on the surface of vinegar, and it is formed by the acetic acid bacteria 
and extracellular cellulose.  In this study, pomegranate vinegar and apple cider vinegar and 
their mother were compared for their amount of bioactive substances.  There were some 
interesting detailed data reported.  The mother of the vinegar had lower pH than the vinegar 
itself (apple cider vinegar pH 4.4± 0.9, mother of apple vinegar pH 3.23 ± 0.09, 
pomegranate vinegar pH 2.98 ± 0.09, mother of pomegranate vinegar pH 2.91 ± 0.08).  On 
the website, many posts stated that organic apple cider vinegar with mother worked superior 
than other kinds of vinegar on the market.  Following our rationale for this study, 
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pomegranate vinegar with mother would be ideal for inducing movement of the esophageal 
body because it had a lower pH, which meant more protons available.  Although the result 
concluded that pomegranate vinegar with mother had better antioxidant function and more 
phenolic substance, apple cider vinegar with mother had much higher Fe and Na elements.  
Additionally, apple cider vinegar was composed of both chlorogenic aicd and gallic acid, 
unlike pomegranate had only gallic acid (Aykin, Budak & Guzel-Seydim, 2015).  A research 
showed chlorogenic acid was beneficial in managing hypertension (Zhao, Wang, Ballevre, 
Luo & Zhang, 2011).    
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CHAPTER 3 
METHODOLOGY 
Participants and Study Design 
 The recruitment of this research started after the Arizona State University 
Institutional Review Board, Human Subjects Committee's approval (Appendix A).  Written 
informed consent was signed by each subject before the trial started (Appendix B).  Subjects 
were recruited from a campus population through School of Nutrition & Health Promotion 
program List Serves, newspaper ads, distribution of printed flyers, and word-of-mouth. 
This was a randomized, placebo-controlled, double-blind, cross-over study.  Subjects 
were randomly assigned different sequences of four treatments (chili - placebo, antacid after 
chili meal - positive control, vinegar added to chili and diluted vinegar after chili meal), with 
one week apart.  Each subject in the study served as a control for his/her trials.        
The applicable sample size (Appendix C) was calculated using the data from two 
previous studies that have results of similar outcome variables (Hartono et al., 2011; 
Collings, 2002).  15 subjects (12 females and 3 males) who were 18 years or older (mean age, 
39.6 ± 12.2 years; range, 21-51 years) were recruited for this study.  Subjects reported 
heartburn symptoms related to GERD were otherwise healthy by self-report. 
All subjects were screened for the willingness to follow the study design included 
ingesting heartburn-inducing chili on four occasions and visiting the Arizona State 
University’s downtown Phoenix campus five times during the trial, and four of the visits 
would be two hours long.  They were also instructed to stop heartburn medication three 
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days before each testing day.  Female volunteers were excluded if they were pregnant or 
lactating.  Subjects were excluded as well if they had pulmonary, renal or heart problems; had 
peptic ulcers or had gastric cancer; had any abdominal surgery; had been diagnosed with 
Barrett's esophagus, hiatal hernia, adenocarcinoma or asymptomatic ERD; or had been 
prescribed PPI treatment at the time of recruiting.  The exclusion criteria questionnaire was 
created with the Survey Monkey website. 
Heartburn-Induced Meal and Symptom Assessment 
 On each testing day, subjects arrived in a fasting state, no food or beverage for the 
last 10 hours but water was allowed.  A baseline heartburn symptom was recorded prior to 
consuming the heartburn-inducing meal.  The meal consists of: 1) 250 grams of chili with 
the heartburn-inducing ingredients, such as onions, tomato and fatty ground meat etc.  All of 
the chili was cooked at once and each serving was divided into zip lock containers and 
stored in the freezer through out the whole study.  The chili recipe is included in the 
appendices (Appendix D).  2) A carton of eight fl. ounce of chocolate milk (Rodriguez et al., 
1998; Holloway et al., 1985).    Twenty grams of apple cider vinegar (Bragg® Organic Raw 
Apple Cider Vinegar, Unfiltered, with the 'Mother') was used for both vinegar trials.  During 
vinegar added to the chili trial, vinegar was added after the chili was heated in the 
microwave.  The other three trials were offered with regular chili.  Participants set off their 
timers right before they started eating, and they were asked to finish the meal in 15 minutes.  
At 15-minute mark, the after meal drink was consumed.   Water was used to dilute 10 grams 
of liquid antacid (each 5 ml teaspoon contains: calcium 400 mg and magnesium 85 mg; 
Rolaids® Ultra Strength Liquid, cherry flavor), and 20 grams of vinegar to 60 grams of after 
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meal drink.  Water with food color dye was used for the placebo trial.  Gift cards were given 
at the end of each treatment visit at value of $10, $10, $15, $15 respectively. 
The postprandial heartburn symptom assessment began at the first sign of heartburn 
symptom.  Then 15 minutes after the start of the meal, with 5-minute intervals between 15 
to 30 minutes, and then 15-minute intervals afterward until the total time span since the start 
of the meal was 120 minutes.  Referring to previous studies, two methods were used to 
assess heartburn symptoms in this research: 1) 0 to 10-cm visual analogue scale (VAS) 
ranging from 'no pain' to 'unbearable pain', and 2) 1 to 5 five-point Likert scale ranging from 
'none' to 'severe' (Appendix D) (Bytzer, 2004; Collings, 2002).  During the two-hour testing 
period, subjects could walk around or sit upright, but were not allowed to rest at a supine 
position or recline.   
Statistical Analyses 
 The Statistical Package for Social Sciences (SPSS) software version 22 was used for 
the statistical analyses of the research data.  Shapiro-Wilk was used to check normality.  
Sphericity Assumptions was used to check the repeated measure had equal variances.  If the 
Sphericity Assumptions was violated (Epsilon ˂ 0.75), then Greenhouse-Geisser adjustment 
was applied to obtain corrected degree of freedom and interpret F-values, and hence an 
adjusted p-value.  ANOVA repeated measure was used to compare the mean heartburn 
scores during the 120-minute testing time and incremental area-under-the-curve (iAUC) data 
of four trials.  The level of statistical significance is P < .05.  Mean and standard deviation 
(SD) will be stated as the results of variable analysis. 
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CHAPTER 4 
RESULTS 
Descriptive Characteristics 
 Forty people responded to the recruitment survey; 31 people met inclusion criteria; 
15 people responded to the interview appointment, and signed the consent.  The consent 
form (Appendix B) was translated into Spanish because many of the participants' first 
language was Spanish and they were not fluent in English.  Out of the 15 participants, 
subject #8 was disqualified because she smoked cigarettes.  14 people were randomly 
assigned to different sequences of four treatments, each with at least one week apart.  
Subject #5 did not show up at the first trial and dropped out; subject #7 and #10 had to be 
discontinued with their trials because of surgeries unrelated to the study.  Data were 
collected from 11 participants (3 males, 8 females) who finished all four trial arms; however 
four participants were excluded from the data calculation because they did not display 
heartburn symptoms in all four trials (n=3), or did not follow the protocol (n=1).  Hence, 
data from seven participants (1 male, 6 females) were used to assess the effect of vinegar on 
the alleviation of heartburn symptoms using the five-point Likert scale (Appendix D).  Due 
to missing data, data from only six participants was available for the visual analogue scale 
(VAS) assessment (Appendix D). 
 Table 2 displays baseline demographic profiles of the seven participants whose data 
were used for hypothesis testing.  The age of the participants averaged 39.6 ± 12.2 years 
(range: 21 to 51 years old).  Body Mass Index (BMI) was 29.4 ± 4.2 kg/m2, (range: 23.1 to 
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35.2 kg/m2).  Three out of seven participants were overweight (BMI= 25 to 29 kg/m2), and 
three out of seven participants were obese (BMI ≥ 30 kg/m2). 
Table 2 
Participants demographic profiles (n=7) 
Variables Number Mean ± SD1 Min-Max 
Gender (M/F) 1/6   
Age (year)  39.6 ± 12.2 21 - 51 
Height (cm)  161.6 ± 9.5 150 - 175 
Weight (kg)  76.5 ± 10.4 55.5 - 86.6 
BMI (kg/m2)  29.4 ± 4.2 23.1 - 35.2 
Fat (%)  36.8 ± 7.7 25.1 - 43.8 
FFM (kg)  48.0 ± 7.0 40.6 - 61.6 
Waist circumference (cm)  92.4 ± 10.3 74.5 - 101.5 
1SD = Standard deviation 
 
Heartburn Study 
 Table 3 displays the heartburn scores of seven participants from baseline (Time 0) to 
120 minutes on the five-point Likert scale: Scale 1 representing no heartburn to scale 5 
representing very severe heartburn.  All subjects were asked to consume the chili in 15 
minutes, and the timer was started just before the participants started eating the chili.  Table 
4 contains the heartburn scores from the VAS.  Participants recorded their severity of 
heartburn at each designated time by putting a mark on a 10 centimeter continuous 
horizontal line ranging from no pain to unbearable pain.  For the purpose of equal time 
spans in the graphs among heartburn scores, heartburn scores before minute-15 and at 
minute-20 and minute -25 were not included in the data analysis.  Therefore all the heartburn 
scores recorded in the graphs were at 15-minute intervals during the 120-minute recording 
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period (Figures 1 and 2).  Incremental area-under-the-curve (iAUC) for heartburn scores was 
calculated using the method recommended in a 2004 article by Wolever.  iAUC data from 
both scales (n=7) met Shapiro-Wilk normality test.  Sphericity assumption was met for both 
questionnaire heartburn scores and iAUC Likert scale data.  iAUC VAS data violated 
Sphericity assumption, and Greenhouse-Geisser, which has middle range of conservation, 
was used to adjust the p-value.  ANOVA repeated measure was used to compare the four 
trial arms of the mean heartburn scores during the 120 minutes testing time and the iAUC 
heartburn score of each treatment (Table 3, 4, 5).  Even though the graph shows a lower 
heartburn score with vinegar after the chili and antacid trials during the first hour period, and 
a lower heartburn score with antacid trial during the second hour period, there is no 
statistically significant difference among the mean and iAUC heartburn scores among 
different trials (Likert scale questionnaire p= .259, VAS questionnaire p= .659, iAUC Likert 
scale p= .184, iAUC VAS p= .326).  The Bar graphs show there is much standard deviation 
(SD) overlaps among iAUC heartburn scores in different trials, which indicates no 
significant difference in heartburn alleviation with different treatments (Figure 3 and 4). 
Table 3 
Heartburn score questionnaire five-point Likert scale1 (Mean ± SD) (n=7) 
Time 
(Minutes) 
Control Vinegar In Vinegar Out Antacid  
0 1.14 ± 0.4 1.14 ± 0.4 1.14 ± 0.4 1.14 ± 0.4  
15 2 ± 0.8 2.29 ± 1.0 1.86 ± 0.7 2 ± 0.8  
30 2.43 ± 0.8 2.43 ± 1.1 2.29 ± 0.8 2.14 ± 0.7  
45 2.57 ± 0.5 2.43 ± 1.1 2 ± 0.8 2 ± 0.8  
60 2.57 ± 1.0 2.71 ± 1.0 2 ± 0.8 2 ± 0.8  
75 2.71 ±  1.3 2.71 ± 1.0 2.29 ± 0.8 2 ± 0.8  
90 2.71 ±  1.3 3.14 ± 0.7 2.57 ± 1.0 2.14 ± 1.1  
105 2.71 ±  1.3 3 ± 1.0 2.86 ± 1.2 2.14 ± 1.1  
120 3 ± 1.2 3 ± 1.0 2.71 ± 1.1 2.14 ± 1.1  
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P Value     .259 
Effect Size    .444 
1 Scale 1-5, (1) None, (2) Mild, (3) Moderate, (4) Severe, (5) Very Severe. 
2 P value obtained through ANOVA repeated measure test. 
 
Table 4 
Heartburn score questionnaire VAS1 (Mean ± SD) (n=6) 
Time 
(Minutes) 
Control Vinegar In Vinegar Out Antacid  
0 0.1 ± 0.2 0.35 ± 0.9 0.13 ± 0.3 0.6 ± 1.3  
15 2.67 ± 1.9 2.37 ± 2.0 2.68 ± 2.4 2.85 ± 2.1  
30 3.6 ± 1.1 2.62 ± 2.8 3.1 ± 2.8 3.05 ± 2.2  
45 3.45 ± 1.4 3 ± 2.8 2.57 ± 2.5 2.43 ± 2.2  
60 3.55 ± 2.2 3.65 ±  2.4 2.57 ± 2.5 2.52 ± 2.1  
75 3.93 ±  2.9 3.75 ± 2.5 3 ± 2.6 2.33 ± 2.1  
90 4.02 ±  3.1 4.73 ± 2.0 4.2 ± 2.6 2.62 ± 2.8  
105 4.42 ±  3.2 4.63 ± 2.0 4.98 ± 3.0 2.65 ± 2.8  
120 4.63 ± 3.2 4.97 ± 1.9 5.08 ± 3.2 2.58 ± 2.7  
P Value2     .659 
Effect Size     .232 
1 Visual analogue scale 0-10, 0 = no pain, 10 = unbearable pain. 
2 P value obtained through ANOVA repeated measure. 
 
 
 
 
 
Table 5 
Heartburn score iAUC1 (Mean ± SD) 
  
iAUC Control Vinegar In Vinegar Out Antacid 
P 
Value2 
Effect 
size 
Likert 
Scale3 
161.79 ± 
117.4 
175.36 ± 
109.8 
130.36 ± 
94.0 
105.36 ± 
87.9 
.184 .425 
VAS4 
389.18 ± 
209.5 
393.75 ± 
267.5 
336.96 ± 
237.8 
230.13 ± 
218.2 
.326 .611 
  46 
 
Figure 1. Postprandial incremental heartburn scores after chili meals using a five-point Likert 
scale (1. None, 2 Mild, 3 Moderate, 4 Severe, 5 Very Severe) under four experimental 
conditions: control, vinegar added to the chili, diluted vinegar after chili meal and antacid 
after chili meal.  Inlay chart depicts mean heartburn score for each experimental condition at 
each time point.  (Horizontal axis, unit = minutes). 
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Figure 2. Postprandial incremental heartburn scores after chili meals using a 10-centimeter 
visual analogue scale (0 = no pain, 10 = unbearable pain) under four experimental 
conditions: control, vinegar added to the chili, diluted vinegar after chili meal and antacid 
after chili meal.  Inlay chart depicts mean heartburn score for each experimental condition at 
each time point.  (Horizontal axis, unit = minutes). 
 
Figure 3. Postprandial incremental heartburn scores after chili meals using a five-point Likert 
scale under four experimental conditions: 1. Control (CON), 2.Vinegar added to the chili 
(VIN), 3.Diluted vinegar after chili meal (VINOUT) and 4.Antacid after chili meal (ANTA).  
Inlay chart depicts iAUC heartburn score (mean ± SD) for each experimental condition 
(P=.184). 
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Figure 4. Postprandial incremental heartburn scores after chili meals using a visual analogue 
scale under four experimental conditions: 1. Control (CON), 2.Vinegar added to the chili 
(VIN), 3.Diluted vinegar after chili meal (VINOUT) and 4.Antacid after chili meal (ANTA).  
Inlay chart depicts iAUC heartburn score (mean ± SD) for each experimental condition 
(P=.326).  1Visual analogue scale n=7, except antacid trial n=6 
Antacid Responding Circumstance 
After carefully reading the graphs of each individual participant's mean heartburn 
data (Appendix F) during four trail-arms, an interesting phenomenon was noticed.  Some 
participants responded well to antacid, but not as much for the others.  Hence, seven 
participants were divided into two groups: Antacid non-responder and antacid responder.  
The criterion to assign a participant to the antacid responder group was that his/her mean 
heartburn data scored below three on the VAS during the whole 120-minute span of the 
individual’s antacid trial.  Except #14 who was missing VAS data in antacid trial day, so the 
Likert scale heartburn number no larger than 2 was used to assign her the antacid responder 
group.  The decision of using mean heartburn score less than three on the VAS as the 
criterion was made by perceiving that when a participant marked mild heartburn on the 
Likert scale (2 out of 5) generally corresponding to the VAS at around or less than 3 cm on a 
10 cm line. 
Likert scale iAUC data from antacid non-responder group (n=3) met Shapiro-Wilk 
normality test, but not VAS iAUC data.  ANOVA repeated measure was used to compare 
the difference of the mean heartburn scores during the total 120 minutes testing time and 
the iAUC heartburn score of each treatment (Table 5, 6, 7).  All of the data in this group 
violated Sphericity assumption, and Greenhouse-Geisser adjustment was used to obtain the 
p-values.  Effect size was not available for any of data in this group due to not enough data. 
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Table 6 
Heartburn score questionnaire Likert scale1 (Mean ± SD) - Antacid non-responder (n=3) 
Time 
(Minutes) 
Control Vinegar In Vinegar Out Antacid  
0 1.33 ± 0.6 1.33 ± 0.6 1.33 ± 0.6 1.33 ± 0.6  
15 2.33 ± 0.6 2.0 ± 1.0 2.0 ± 1.0 2.67 ± 0.6  
30 2.67 ± 0.6 2.33 ± 1.5 2.33 ± 1.2 2.67 ± 0.6  
45 2.67 ± 0.6 2.0 ± 1.7 2.0 ± 1.0 2.67 ± 0.6  
60 2.67 ± 2.2 2.33 ± 1.5 2.0 ± 1.0 2.67 ± 0.6  
75 3.0 ± 2.9 2.33 ± 1.5 2.33 ± 0.6 2.67 ± 0.6  
90 3.0 ± 3.1 3.0 ± 1.0 3.0 ± 1.0 3.0 ± 1.0  
105 3.0 ± 3.2 3.33 ± 0.6 3.33 ± 1.2 3.0 ± 1.0  
120 3.33 ± 3.2 3.33 ± 0.6 3.0 ± 1.0 3.0 ± 1.0  
      
P-value2     .807 
Effect Size     N/A 
1 Scale 1-5, (1) None, (2) Mild, (3) Moderate, (4) Severe, (5) Very Severe.  2 P-value 
obtained through ANOVA repeated measure.  Greenhouse-Geisser adjustment is used. 
 
 
 
Table 7 
Heartburn score questionnaire VAS1 (Mean ± SD) - Antacid non-responder (n=3) 
Time 
(Minutes) 
Control Vinegar In Vinegar Out Antacid  
0 0.2 ± 0.4 0.7 ± 1.2 0.27 ± 0.5 1.2 ± 1.7  
15 2.6 ± 1.2 1.83 ± 1.7 2.43 ± 2.6 4.27 ± 1.9  
30 3.57 ± 0.7 2.3 ± 3.6 3.4 ± 3.0 4.5 ± 1.9  
45 3.2 ± 1.4 2.3 ± 4.0 2.3 ± 2.3 4.03 ± 1.4  
60 3.37 ± 3.1 3.23 ± 3.7 2.33 ± 2.3 4.2 ± 0.6  
75 4.23 ± 4.4 3.3 ± 3.8 2.4 ± 2.2 3.77 ± 1.6  
90 4.37 ± 4.6 4.63 ± 3.0 4.6 ± 2.3 4.3 ± 2.8  
105 4.43 ± 4.7 5.23 ± 2.4 5.43 ± 2.6 4.33 ± 2.8  
120 4.53 ± 4.5 5.93 ± 1.6 5.13 ± 2.6 4.3 ± 2.8  
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P Value2     .837 
Effect Size     N/A 
1 Visual analogue scale 0-10, 0 = no pain, 10 = unbearable pain.   2 P value obtained 
through ANOVA repeated measure.  Greenhouse-Geisser adjustment is used. 
 
 
 
 
 
 
 
Table 8 
Heartburn score iAUC1 (Mean ± SD) - Antacid non-responder (n=3) 
  
iAUC Control Vinegar In Vinegar Out Antacid P Value2 
Effect 
size 
Likert 
Scale 
170 ± 191.5 
136.67 ± 
177.1 
129.17 ± 
130.5 
163.08 ± 
113.4 
.776 N/A 
visual 
analogue 
scale 
409.83 ± 
328.8 
307.25 ± 
429.8 
356.33 ± 
226.0 
341.08 ± 
245.0 
.761 N/A 
1 iAUC = incremental area-under-the-curve.  
2 P value obtained through ANOVA repeated measure.  Greenhouse-Geisser adjustment is 
used for both scales. 
 
  51 
 
Figure 5. Postprandial incremental heartburn scores after chili meals using a five-point Likert 
scale (1. None, 2 Mild, 3 Moderate, 4 Severe, 5 Very Severe) under four experimental 
conditions: control, vinegar added to the chili, diluted vinegar after chili meal and antacid 
after chili meal.  Inlay chart depicts mean heartburn score for each experimental condition at 
each time point.  (Horizontal axis, unit = minutes). 
 
Figure 6. Postprandial incremental heartburn scores after chili meals under four experimental 
conditions: control, vinegar added to the chili, diluted vinegar after chili meal and antacid 
after chili meal.  Inlay chart depicts mean heartburn score for each experimental condition at 
each time point.  (Horizontal axis, unit = minutes).  1 Visual analogue scale 0-10, 0 = no pain, 
10 = unbearable pain. 
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Figure 7. Postprandial incremental heartburn scores after chili meals using a five-point Likert 
scale under four experimental conditions: 1. Control (CON), 2.Vinegar added to the chili 
(VIN), 3.Diluted vinegar after chili meal (VINOUT) and 4.Antacid after chili meal (ANTA).  
Inlay chart depicts iAUC heartburn score (mean ± SD) for each experimental condition 
(P=.776). 
 
Figure 8. Postprandial incremental heartburn scores after chili meals using a visual analogue 
scale under four experimental conditions: 1. Control (CON), 2.Vinegar added to the chili 
(VIN), 3.Diluted vinegar after chili meal (VINOUT) and 4.Antacid after chili meal (ANTA).  
Inlay chart depicts iAUC heartburn score (mean ± SD) for each experimental condition 
(P=.761). 
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Both iAUC data from antacid responder group (n=4) met Shapiro-Wilk normality 
test.  ANOVA repeated measure was used to compare the difference of the mean heartburn 
scores during the total 120 minutes testing time and the iAUC heartburn score of each 
treatment (Table 9, 10, 11).  Only Likert scale iAUC data met Sphericity assumption, and 
Greenhouse-Geisser adjustment was used to obtain the p-values for the rest of data in this 
group.  Likert scale iAUC p= .017, and the significance was heartburn scores between 
vinegar added to the chili trial and antacid trial. The effect size from the iAUC Likert scale 
data was .936.  Another significant p-value was mean heartburn score data for Likert scale 
p= .034 with effect size .967.  VAS iAUC and mean heartburn scores effect size were 
unavailable, and iAUC p= .203, and mean heartburn score p= .205.   
 
Table 9 
Heartburn score questionnaire Likert scale1 (Mean ± SD) - Antacid Responder (n=4) 
Time 
(Minutes) 
Control Vinegar In Vinegar Out Antacid  
0 1 ± 0 1 ± 0 1 ± 0 1 ± 0  
15 1.75 ± 1.0 2.5 ± 1.0 1.75 ± 0.5 1.5 ± 0.6  
30 2.25 ± 1.0 2.5 ± 1.0 2.25 ± 0.5 1.75 ± 0.5  
45 2.5 ± 0.6 2.75 ± 0.5 2 ± 0.8 1.5 ± 0.6  
60 2.5 ± 0.6 3 ± 0 2 ± 0.8 1.5 ± 0.6  
75 2.5 ± 0.6 3 ± 0 2.25 ± 1.0 1.5 ± 0.6  
90 2.5 ± 0.6 3.25 ± 0.5 2.25 ± 1.0 1.5 ± 0.6  
105 2.5 ± 0.6 2.75 ± 1.3 2.5 ± 1.3 1.5 ± 0.6  
120 2.75 ± 1.0 2.75 ± 1.3 2.5 ± 1.3 1.5 ± 0.6  
P Value2     .034 
Effect Size     .967 
1Scale 1-5, (1) None, (2) Mild, (3) Moderate, (4) Severe, (5) Very Severe.  2 P value obtained 
through ANOVA repeated measure.  Greenhouse-Geisser adjustment is used. 
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Table 10 
Heartburn score questionnaire VAS1 (Mean ± SD) - Antacid Responder 
Time 
(Minutes) 
Control Vinegar In Vinegar Out Antacid  
0 0 ± 0 0 ± 0 0 ± 0 0 ± 0  
15 2.73 ± 2.3 2.9 ± 2.5 2.93 ± 2.8 1.43 ± 1.3  
30 3.63 ± 1.6 2.93 ± 2.5 2.8 ± 3.2 1.6 ± 1.4  
45 3.7 ± 1.6 3.7 ± 1.3 2.83 ± 3.3 0.83 ± 1.4  
60 3.73 ± 1.4 4.07 ± 0.6 2.8 ± 3.2 0.83 ± 1.4  
75 3.63 ± 1.4 4.2 ± 0.5 3.6 ± 3.3 0.9 ± 1.6  
90 3.67 ± 1.6 4.83 ± 0.7 3.8 ± 3.4 0.93 ± 1.6  
105 4.4 ± 2.0 4.03 ± 1.8 4.53 ± 3.9 0.97 ± 1.7  
120 4.73 ± 2.1 4 ± 2.0 5.03 ± 4.4 0.87 ± 1.5  
P Value2     .205 
Effect Size     N/A 
1 Visual analogue scale 0-10, 0 = no pain, 10 = unbearable pain. N=6.  2 P value obtained 
through ANOVA repeated measure.  Greenhouse-Geisser adjustment is used. 
 
 
Table 11 
Heartburn score iAUC1 (Mean ± SD) - Antacid Responder 
  
iAUC Control Vinegar In Vinegar Out Antacid P Value2 
Effect 
size 
Likert 
Scale3 
155.63 ± 
54.8 
204.38 ± 
24.0 
131.25 ± 
79.4 
68.25 ± 64.5 .017 .936 
visual 
analogue 
scale4 
373.69 ± 
122.3 
458.63 ± 
83.2 
349.44 ± 
280.4 
119.17 ± 
148.5 
.203 N/A 
1 iAUC = incremental area-under-the-curve.   
2 P value obtained through ANOVA repeated measure.  Greenhouse-Geisser adjustment is 
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Figure 9. Postprandial incremental heartburn scores after chili meals using a five-point Likert 
scale (1. None, 2 Mild, 3 Moderate, 4 Severe, 5 Very Severe) under four experimental 
conditions: control, vinegar added to the chili, diluted vinegar after chili meal and antacid 
after chili meal.  Inlay chart depicts mean heartburn score for each experimental condition at 
each time point.  (Horizontal axis, unit = minutes). 
 
 
Figure 10. Postprandial incremental heartburn scores after chili meals using a 10-centimeter 
visual analogue scale (0 = no pain, 10 = unbearable pain) under four experimental 
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conditions: control, vinegar added to the chili, diluted vinegar after chili meal and antacid 
after chili meal.  Inlay chart depicts mean heartburn score for each experimental condition at 
each time point.  (Horizontal axis, unit = minutes). 
 
Figure 11. Postprandial incremental heartburn scores after chili meals using a five-point 
Likert scale under four experimental conditions: 1. Control (CON), 2.Vinegar added to the 
chili (VIN), 3.Diluted vinegar after chili meal (VINOUT) and 4.Antacid after chili meal 
(ANTA).  Inlay chart depicts iAUC heartburn score (means ± SD) for each experimental 
condition (P=0.246). 
 
 
Figure 12. Postprandial incremental heartburn scores after chili meals using a visual analogue 
scale under four experimental conditions: 1. Control (CON), 2.Vinegar added to the chili 
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(VIN), 3.Diluted vinegar after chili meal (VINOUT) and 4.Antacid after chili meal (ANTA).  
Inlay chart depicts iAUC heartburn score (means ± SD) for each experimental condition 
(P=0.163). 
CHAPTER 5 
DISCUSSION 
People with GERD have different etiologies and therefore a wide range of the 
symptom manifestations.  Many previous studies have investigated various possible 
underlying causes of the GERD symptoms, with different approaches and suggestions to 
reducing the heartburn that occurred.  This study was to investigate how the ingestion of 
organic vinegar with mother, acetic acid, affects the intensity of heartburn related to GERD.   
Even though the result shows no statistically significant difference among each treatment 
trial (vinegar added to the chili meal, vinegar after chili meal or antacid) and the placebo trial, 
the effective size indicated that according to the result data, there was a large difference 
among each intervention. 
Effect Size 
Due to little available data for analysis, effect size was used to interpret data along 
with p value using ANOVA repeated measure.  Type II error might be made when sample 
size is too small, and a significant change from the intervention could have a non-significant 
p-value.  According to Levine and Hullett in their 2002 article, with null hypothesis, both the 
sample size and the scale of the change due to the interventions affect the p-values.  
Therefore, a measurement fairly independent from the sample size is necessary to observe 
the effectiveness of the intervention (Levine & Hullett, 2002) when usable data from the 
participants was not corresponding to the original calculated recruitment size (Appendix C), 
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either too much or too little.  According to Cohen et al. in their 2001 article, the formula 
used would be leading more toward partial eta-squared than eta-squared.  Effect size when 
using ANOVA (η2), the strength of the relationship between the factor and the dependent 
variable or the degree of the difference between groups, is as follows: Small= 0.02, 
Medium= 0.13 and Large= 0.26 (Cohen, Miles & Shevlin, 2001).  Effect size in this study 
was analyzed by Multivariate Tests effect: partial eta squared. 
Interesting Data Findings 
Some interesting data were observed from studying each individual participant's 
heartburn rating during four trial arms.  Among seven participants, one treatment might 
have worked very well for a few people, but the same treatment caused more heartburn in 
others.  This phenomenon was observed in all three treatments.  For people who responded 
well to antacid, vinegar added to the chili might cause more heartburn than the chili alone in 
the placebo trial.  Likert scale mean heartburn scores showed significant p-value of .026 
between antacid treatment and vinegar added to the chili treatment in the antacid responder 
group.  Oddly, in the same group, when diluted vinegar was ingested after the chili meal, it 
appeared to lower the heartburn intensity during the first hour comparing to the placebo trial 
although the effect was not as pronounced as antacid.  For people who did not respond to 
antacid, according to the VAS graph, antacid might cause more heartburn than the chili 
alone in the placebo trial.  Interestingly, among three participants in the antacid non-
responder group, one responded very well with diluted vinegar, but vinegar added to the 
chili caused the worst heartburn among four trials.  Yet, another responded better when 
vinegar was in the chili, while the last participant responded well to both vinegar treatments.  
This phenomenon might be due to the fact that the participants were in a different 
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subcategory or had a different etiology of GERD, and it also explained the huge overlap of 
the SD in the result.  Another interesting observation was that, for people who responded to 
vinegar treatment, the effect only lasted 60 to 75 minutes, and then the heartburn intensity 
might increase afterwards. 
Another interesting outcome was discovered after noticing lower heartburn scores in 
the placebo treatment when a few participants had CON trial at their fourth week.  The sum 
of the mean heartburn scores (n=8) was decreasing as the study progressed, regardless of the 
treatment sequences.  The data of the participant, who did not follow the protocol and drank 
her after-meal beverage at the 60-minute mark instead of the 15-minute mark, was included 
in this data analysis because the comparison was focused on the mean heartburn score of the 
test day, not the time of each trial.  Therefore, even though she applied the treatments later 
than the protocol, her mean heartburn score of the day still could be used for comparison 
with her other three trials.  The current study used cross-over design, which does not 
address "learned effect" from the participants during the trials.  A brain processing for the 
perceived heartburn threat after the first week of treatment might explain this outcome.  
Siwiec et al. has demonstrated that the amygdala and hippocampus were involved with the 
esophageal afferent signal processing (Siwiec et al., 2015).  The amygdala and hippocampus 
are part of the default mode network, within which part of its tasks is detecting a threat and 
readying the body for an automatic response.  The participants who joined the study had 
agreed to ingest heartburn inducing chili for four trials, on the same day of the week, and at 
the same time of the day.  In real life, we do not operate in this manner.  The heartburn 
inducing chili meal, which was presented to the participants, had a more parallel meaning to 
a hole in the road on the way to work than a spontaneous meal, which may or may not 
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induce heartburn.  Further research is needed to investigate this learned effect and the 
suitability of the cross-over design in the subjective based study. 
Considerations for Future Study Design  
There were several opportunities to make improvements for the next study design.  
First, we had a surprisingly high prevalence of the Spanish speaking population in our 
participants, and there were not many studies targeting heartburn symptoms in the Hispanic 
population.  It would be beneficial to have an ethnic question added to the medical history 
questionnaire, and the comparison among different ethnicity could be performed as well. 
Second, the heartburn assessment methods in the current study replicated the study 
Collings et al. did in 2002, investigating how antacid chewing gum affected heartburn and 
pH in the esophagus (Collings et al., 2002).  During the trials, most of the participants would 
mark the heartburn score on the Likert scale sheet, and then marked a corresponding 
position on the VAS line where the heartburn intensity was on the Likert scale sheet.  
Understandably, when two pieces of paper put side by side with similar orientation to mark 
the same symptom, it is very easy to make marks at the same location on each paper.  The 
problem with this approach was that the marks on the VAS lines were not being mindfully 
considered.  Furthermore, they were confined by the dots on the Likert scale sheet, instead 
of being treated as a continuous line.  The purpose of a continuous line was to distinguish 
the different degree of each status of heartburn on the Likert scale.  For example, a mild 
heartburn could range from 0.2 to around 3.5 cm on a VAS line, and as time changes, the 
heartburn symptom might change its intensity in that range despite the fact that it would still 
be a mild heartburn on the Likert scale.  Unfortunately, the VAS graphs did not show the 
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details of the change we were looking for, except for the graphs from a few participants.  
After carefully reading the data, it might be valuable to only use VAS assessment for 
heartburn symptoms, or having one scale in portrait orientation and the other one in 
landscape placement to break up the automatic transferred thinking pattern. 
Third, when working with the participants who do not speak the same language, a 
translator who understands the details in the study protocol is necessary.  Trying to explain 
the protocol with different languages might create confusion and disturb the trial 
progression.  Besides, it was hard to know if the participants understood the conversation. 
Fourth, a fair design flow for all treatments should have liquid antacid and diluted 
vinegar drank right at the beginning of the meals, so they would start to work almost the 
same time as the vinegar added to the chili trial.  In our current study design, vinegar added 
to the chili started 15 minutes earlier than the other two treatments.   
Additionally, pinching the nose could be a reinforced protocol instead of a 
suggestion to reduce the strong smell of vinegar especially when drinking the diluted vinegar.  
Pinching the nose and reducing the pungent smell could also reduce the possibility of 
aspiration of vinegar into a wrong pipe. 
There was an issue during the recruitment phase.  We would like to recruit only 
people who would get heartburn symptom from eating our chili meal, so a sample was 
provided on the interview day.  However, we could not let the volunteer try our chili without 
signing the consent form, and therefore, we needed to recruit the volunteer before we knew 
if he/she would have heartburn symptoms after eating chili.  Using the actual amount of 
chili in the trial as a sample might also be helpful.  During the trials, some participants could 
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not finish the whole bowl while a male participant mentioned the amount was too little to 
induce heartburn for him. 
Possible Rationale for Data Interpretation  
Antacid responder.  The possible explanation for how vinegar caused more 
heartburn for some participants, especially the ones who responded to antacid well, is the 
following.  For people who have damages to their esophageal epithelium because of 
prolonged acidic reflux, chili could pass the stratified squamous layer and irritates the 
mucosa layer below.  While vinegar is a weak acid, it could still create more irritation to these 
participants than the chili alone.  The pH for the chili in the control trial was 4.76, and in the  
VININ trial, the chili pH was 4.4.  Contradictorily, diluted vinegar seemed provide some 
heartburn relive for this group.  The possible reason could be diluted vinegar had more 
protons available than the one mixed in the chili.  Diluted vinegar in VINOUT trial pH was 
3.02.  Dutta et al. demonstrated that acid infusion in the upper third part of the esophagus 
significantly increased saliva secretion (Dutta et al., 2010).  While most of the damaged 
esophageal epithelium was located at distal part of the esophagus, the saliva might have 
neutralize the content, and increased primary peristalsis from swallowing extra saliva might 
help to clear the esophagus as well.  Especially Bontempo et al. mentioned that during 
esophageal acidification, the primary peristalsis activated by deglutitions had increased 
duration and amplitude and decreased propagation velocity (Bontempo et al., 1994).  
Therefore, ingestion of vinegar might provide a better esophageal clearance for GERD 
patients whose etiology is not hyposensitive esophageal mucosa to acid stimulation, such as 
patients with asymptomatic ERD. 
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Antacid non-responder.  Even though not statistically significant, we observed that 
participants, who did not respond to antacid well, had lower heartburn intensities during the 
first 60 minutes in at least one vinegar trial when comparing to the placebo.  Before we 
hypothesize the mechanisms which might happen in the esophagus or the stomach after 
ingestion of organic vinegar with mother, that could help reduce the sensation of heartburn, 
it is helpful to review the results and proposals of previous research that are highly related to 
the association among the esophagus, reflux episode, acid infusion and nervous system in 
the esophagus.  As earlier described in the subcategories of GERD section, people with 
NERD or FH had very high refractory rates of PPI treatment.  Their reflux content could be 
neutral or the heartburn sensation could occur even without the existence of reflux episode 
respectively.  Zerbib et al. mentioned that anti-reflux therapy, such as PPI, worked much 
better with patients who had a normal esophageal acid exposure, and their heartburn 
symptoms and reflux episodes correlated closely (Zerbib et al., 2012).  In the esophagus 
section, we pointed out the distinguishing function of chemonociception vagal afferents and 
mechanical stimuli perception spinal afferents.  Dutta et al. and Bontempo et al. showed acid 
infusion in the human esophagus increased salivation secretion and the frequency of dry and 
wet swallowing (Dutta et al., 2010; Bontempo et al., 1994).  Furthermore, in the brain 
processing section, Siwiec et al suggested that abnormal highly active sensory afferents in the 
esophagus could be an important underlying factor for NERD patients (FH included) 
(Siwiec et al., 2015).  Corazziari et al. also showed that acid infusion affected secondary 
peristalsis, and although a pH of 5 to 7 could elicit secondary peristalsis in the lower 
esophageal body, an infusion of a pH of 4 or below, significantly reduced the volume needed 
to produce esophageal motor activity in normal participants (Corazziari, Pozzessere, Dani, 
Anzini & Torsoli, 1978).  Therefore, theoretically, in this study, the diluted vinegar in 
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VINOUT trial, at pH 3.02, could produce esophageal secondary peristalsis.  However, more 
research is needed to evaluate the change of the vinegar pH at the upper third and the 
bottom third of the esophagus, and how it might affect GERD patients.   
Since this current study does not have any intraluminal esophageal data available, this 
hypothesis is only an inference and will need further research to investigate.  Generally 
people who do not respond to antacids well, might either have a neutral reflux content or 
highly active afferents in the esophagus or both.  Therefore, while the spinal afferent senses 
the distention of the esophagus or perceives something in the esophagus, the vagal afferent 
detects no acid from its chemonociceptors.  It has been suggested that vagal afferent (acid 
sensitive) could elicit secondary peristalsis; increase salivation secretion; increase frequency 
of dry and wet swallowing, which induces the primary peristalsis from somatic striated 
skeletal muscle.  The mechanisms mentioned prior have two purposes, to neutralize the 
content in the esophagus and clear the esophagus by pushing the content down to the 
stomach.  Without the protons from the acid (a noxious chemical), these mechanisms could 
not happen, however, the spinal afferents continue sending a sensory signal of discomfort.  
By ingesting organic vinegar with mother, it would start the esophageal primary peristalsis.  
It might provide protons that are needed in the esophagus to activate the vagal afferents and 
consequent mechanisms.  It might also stimulate gastric juice secretion in the stomach 
because of high amount of microbes gained during the fermentation process, and hence a 
prominent proton source.  It is debatable that vinegar is a weak acid, and its protons do not 
disassociate from its salt easily.  The hypersensitive afferents in some NERD and FH 
patients might react to weak acid differently than normal people, and their vagal afferents 
might be able to be stimulated with less proton or less acidic content.  Additionally, for some 
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patients with FH diagnosis, heartburn sensation could occur without the actual reflux 
episode.  While there might not be something to clear in their esophagus, the consequent 
mechanisms due to activated vagal afferents might still provide a sense of relive to the spinal 
afferents in the esophagus. 
CHAPTER 6 
CONCLUSION 
This is the first study to investigate the association between acid and heartburn 
symptoms related to GERD from a beneficial point of view.  The acid chosen for the study 
was organic apple cider vinegar with mother.  In summary, the results of our study support 
our second null hypothesis - compared to the placebo trial, the vinegar trials do not show 
significant alleviation of the heartburn sensation. 
After seven participants further divided into antacid responders and non-responder 
groups, antacid showed significant alleviation of the heartburn sensation when compared to 
vinegar added to the chili trial in the antacid responder group.  This result only supports part 
of our first null hypothesis because there was no significant difference between diluted 
vinegar after chili and antacid trials.  The results also resemble those of previous studies on 
GERD which proposed the gap theory, which states that the content in the esophagus might 
leak through damaged esophageal epithelium lining and therefore cause heartburn.   
Interestingly, the graph data changed after the participants were divided into two different 
groups, according to their antacid responding circumstance, which supports the conclusions 
from previous research that GERD patients have varied pathophysiology and the same 
symptoms might have diverse underlying etiologies.  Although not statistically significant, 
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ingestion of organic vinegar appeared to alleviate heartburn symptoms for some individuals, 
however, the effect seemed to last only for the first 60 to 75 minutes.  The effect size 
through ANOVA from the available data showed either there was a great association 
between the treatment and the heartburn score or there was a large degree of the difference 
among trials. 
Further research is needed to target the population in the same GERD subcategory 
and investigate if this approach would bring a more similar heartburn response among the 
participants to each treatment in the current study.  A great deal of ongoing research 
continues investigating the complicated etiologies of GERD, and it might not be feasible to 
try to identify the GERD etiology of each participant.  It would be interesting to investigate 
the underlying reason for the upsurge of heartburn symptoms at the second hour for several 
individuals.  More research is necessary to confirm the organic apple cider vinegar's effect on 
antacid responders and non-responders. 
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DIET STRATEGIES TO IMPROVE REDUCE HEARTBURN SYMPTOMS RELATED 
TO GERD 
 
INTRODUCTON 
The purposes of this form are (1) to provide you with information that may affect your 
decision as to whether or not to participate in this research study, and (2) to record your 
consent if you choose to be involved in this study. 
 
RESEARCHERS 
Dr. Carol Johnston, a Nutrition professor at Arizona State University Downtown Campus, 
and Zoe Yeh, Nutrition Masters student, have requested your participation in a research 
study. 
 
STUDY PURPOSE 
The purpose of the research is to examine the effects of common food items to relieve 
heartburn symptoms following the consumption of a chili and chocolate milk meal.  The 
chili recipe is expected to evoke symptoms of heartburn, and participants will be asked 
to record symptoms of heartburn for a 2-hour period post meal.     
 
DESCRIPTION OF RESEARCH STUDY 
You have indicated to us that you are 18 years of age or older, a non-smoker and 
generally healthy; however, you have experienced heartburn symptoms related to GERD 
three or more times per week for the preceding three months or longer.  You have not 
been diagnosed with erosive reflux disease or other chronic diseases such as diabetes 
or heart disease, you are not a vegetarian, and (if female) you have not recently been 
pregnant or lactating (past 6 months).    Participants will be asked to maintain their usual 
diet and physical activity level throughout the trial with the exception of the day prior to 
testing. This study will initially involve the completion of a brief medical history 
questionnaire to demonstrate the absence of medical conditions that may impact the 
study.  Your weight, height, and girth will be measured at this time.  This first meeting will 
take about 15 minutes.  There are four additional visits (e.g., the test days) that will last 
about 2 hours each and are scheduled about a week apart. The procedures on test days 
are identical.  On the day prior to testing you are asked to avoid heavy exercise (normal 
activities such as walking to work or walking the dog is ok).  You will be asked to eat a 
normal breakfast and lunch of your choice. The evening before the test day is also a 
meal of your choice, but we will ask you to eat the same dinner meal on the days prior to 
testing (4 days total). Following dinner, you will fast overnight and not consume any food 
or beverage with the exception of water.  On test days, you will travel to ASU (the 
Nutrition labs at the ABC1 Building on the ASU Downtown campus) early in the morning.  
Your finger will be pricked for a blood sample.  You will sit down and consume a test 
meal (chili and chocolate milk).  Your finger will be pricked four more times over the next 
2 hours.  You may drink water during these two hours but you are not to consume any 
food and you cannot lay down.  There will be several short questionnaires to complete at 
scheduled times during these 2 hours to assess the degree of heartburn.  Otherwise, 
you may read, study, or work on the computer at the test site.  Once testing is complete, 
you may proceed with your normal activities.   
 
Finger pricks will be conducted under sterile conditions using disposable, retractable 
lancets, and the level of glucose in blood will be recorded.   
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RISKS 
You will likely develop symptoms of heartburn following the ingestion of the test meal.  
Evoking symptoms of heartburn will allow us to assess the efficacy of a natural treatment 
for heartburn.  We will have TUMS available to relieve symptoms if desired once the 2-
hour test period is over.  Bruising of the skin or a feeling of faintness is possible during 
the finger pricks.  Disposable retractable lancets will be used and sterile conditions will 
be used.   
 
BENEFITS  
There is no direct benefit for participating in this trial.  If desired, you will be provided with 
study results and your personal blood data at the end of the study.    
 
NEW INFORMATION 
If the researchers find new information during the study that would reasonably change 
your decision about participating, then they will provide this information to you.  
 
 
CONFIDENTIALITY 
All information obtained in this study is strictly confidential unless disclosure is required 
by law.  The results of this research study may be used in reports, presentations, and 
publications, but your name or identity will not be revealed.  In order to maintain 
confidentiality of your records, Dr. Johnston will use subject codes on all data collected, 
maintain a master list separate and secure from all data collected, and limit access to all 
confidential information to the study investigators.   
 
WITHDRAWAL PRIVILEGE 
You may withdraw from the study at any time for any reason without penalty or prejudice 
toward you.  Your decision will not incur negative treatment to you by the researchers. 
 
COSTS AND PAYMENTS 
The all test foods will be given to you during the study free of charge.  You will receive a 
$10 Target card at test visits 1 and 2 and a $15 Target cared at test visits 3 and 4 ($50 
total if the study is completed). 
 
COMPENSATION FOR ILLNESS AND INJURY 
If you agree to participate in the study, then your consent does not waive any of your 
legal rights. However, in the event of harm, injury, or illness arising from this study, 
neither Arizona State University nor the researchers are able to give you any money, 
insurance coverage, free medical care, or any compensation for such injury.  Major 
injury is not likely but if necessary, a call to 911 will be placed.  
 
VOLUNTARY CONSENT 
Any questions you have concerning the research study or your participation in the study, 
before or after your consent, will be answered by Dr. Carol Johnston; 500 N. 3rd Street 
Phoenix, AZ 85004; 602-827-2265.  
 
If you have questions about your rights as a subject/participant in this research, or if you 
feel you have been placed at risk, you can contact the Chair of the Human Subjects 
Institutional Review Board, through the ASU Research Compliance Office, at 480-965 
6788.   
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This form explains the nature, demands, benefits and any risk of the project.  By signing 
this form you agree knowingly to assume any risks involved.  Remember, your 
participation is voluntary.  You may choose not to participate or to withdraw your consent 
and discontinue participation at any time without penalty or loss of benefit.  In signing 
this consent form, you are not waiving any legal claims, rights, or remedies.  A copy of 
this consent form will be given to you.   
 
Your signature below indicates that you consent to participate in the above study.   
 
 
_____________________ _________________________ ____________ 
Subject's Signature   Printed Name    Date 
 
 
___________________________ _________________________       
Contact phone number              Email    
 
INVESTIGATOR’S STATEMENT 
"I certify that I have explained to the above individual the nature and purpose, the 
potential benefits, and possible risks associated with participation in this research study, 
have answered any questions that have been raised, and have witnessed the above 
signature. These elements of Informed Consent conform to the Assurance given by 
Arizona State University to the Office for Human Research Protections to protect the 
rights of human subjects. I have provided the subject/participant a copy of this signed 
consent document." 
 
 
Signature of Investigator__________________________        Date_____________ 
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ESTRATEGIAS DE DIETA PARA AYUDAR A REDUCIR Y MEJORAR LOS 
SINTOMAS DE ACIDEZ RELACIONADOS CON ERGE 
 
INTRODUCCION 
El proposito de este formulario es: (1) proporcionarle información que pueda afectar su 
decisión en cuanto a si debe o no participar en este estudio de investigación, y (2) 
registrar su consentimiento si decide participar en este estudio. 
 
INVESTIGADORES 
La Dra. Carol Johnston, Profesora de Nutrición de la Universidad Estatal de Arizona 
Downtown Campus, y Zoe Yeh, estudiante de la maestría en Nutrición, han solicitado su 
participación en un estudio de investigación. 
 
PROPOSITO DEL ESTUDIO 
El propósito de la investigación es examinar los efectos de alimentos comunes para 
aliviar los síntomas de acidez tras el consumo de chili y una bebida de leche 
chocolatada. Se espera que la receta de chili produsca los síntomas de la acidez 
estomacal, y se pedirá a los participantes que registren los síntomas de acidez por un 
período posterior a la comida de 2 horas. 
 
DESCRIPCION DEL ESTUDIO DE INVESTIGACION 
Usted nos ha indicado que tiene 18 años de edad o más, es no fumador y generalmente 
goza de buena salud; sin embargo, usted ha experimentado los síntomas de acidez 
relacionados con la ERGE (Enfermedad por reflujo gastroesofágico) tres o más veces 
por semana durante los pasados tres meses o más. No ha sido diagnosticado con la 
enfermedad de reflujo erosiva u otras enfermedades crónicas tales como la diabetes o 
enfermedades del corazón, usted no es vegetariano, y (si es mujer) no ha estado 
recientemente embarazada o lactando los últimos 6 meses. Se les pedirá a los 
participantes que mantengan su dieta y nivel de actividad física habitual durante todo el 
estudio, con la excepción del día antes de la prueba. Este estudio inicialmente implicará 
la realización de un cuestionario breve de su historial médico para demostrar la 
ausencia de condiciones médicas que pudiesen afectar el estudio. Su peso, altura y su 
circunferencia de cintura se medirán en esta etapa. Esta primera reunión durará unos 
15 minutos. Hay cuatro visitas adicionales (por ejemplo, los días de prueba) que durarán 
alrededor de 2 horas cada una y están programadas con una semana de diferencia. Los 
procedimientos en los días de prueba son idénticos. El día antes de la prueba se le 
pedirá que evite el ejercicio pesado (actividades normales como caminar al trabajo o 
pasear al perro está bien). Se le pedirá comer un desayuno normal y el almuerzo de su 
elección. La noche anterior al día de la prueba es también una comida de se su 
elección, pero se le pedirá que coma la misma comida de la cena en los días previos a 
la prueba (4 días en total). Después de la cena, deberá ayunar durante la noche y no 
consumir ningún alimento o bebida con excepción de agua. En los días de prueba, 
deberá viajar a ASU (los laboratorios de Nutrición en el Edificio ABC1 en el Downtown 
Campus de ASU) temprano en la mañana. Su dedo será pinchado para obtener una 
muestra de sangre. Posteriormente va a sentarse y consumir una comida de prueba 
(chili y leche con chocolate). Su dedo será pinchado cuatro veces más durante las 
siguientes 2 horas. Usted puede tomar agua durante estas dos horas, pero no podrá 
consumir ningún alimento y no podrá recostarse. Habrá varios cuestionarios cortos para 
completar durante estas 2 horas para evaluar el grado de acidez. El resto del tiempo, 
usted puede leer, estudiar o trabajar en su computadora personal en el lugar de la 
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prueba. Una vez que se complete la prueba, puede continuar con sus actividades 
normales. 
Los pinchazos en los dedos se llevarán a cabo en condiciones estériles utilizando 
agujas retráctiles desechables, y se registrará el nivel de glucosa en la sangre. 
 
RIESGOS 
Es probable que usted desarrolle síntomas de acidez estomacal después de comer de 
la comida de prueba. Provocar los síntomas de la acidez estomacal nos permitirá 
evaluar la eficacia de un tratamiento natural para la acidez estomacal. Tendremos 
TUMS disponibles para aliviar los síntomas si se desea una vez que el periodo de 
prueba de 2 horas ha terminado. Si es necesario, vamos a detener las pruebas y 
permitir el uso de un antiácido. Leves moretones en la piel o una sensación de desmayo 
son posibles de ocurrir durante los pinchazos en los dedos. Se utilizarán agujas 
retráctiles desechables en condiciones estériles. 
 
BENEFICIOS 
No hay ningún beneficio directo por participar en este estudio. Si usled desea, se le 
proporcionarán los resultados del estudio y sus datos personales de sangre al final del 
estudio. 
 
NUEVA INFORMACIÓN 
Si los investigadores encontrasen nueva información durante el estudio que pudiera 
cambiar razonablemente su decisión acerca de la participación en este estudio, 
entonces van a proporcionarle esta información a usted. 
 
CONFIDENCIALIDAD 
Toda la información obtenida en este estudio es estrictamente confidencial a menos que 
su difusión sea requerida por la ley. Los resultados de este estudio de investigación 
pueden ser usados en informes, presentaciones y publicaciones, pero su nombre o 
identidad no serán revelados. A fin de mantener la confidencialidad de sus registros, la 
Dra. Johnston utilizará un código numérico en todos los datos recogidos, mantendrá una 
lista maestra separadamente y segura de todos los datos recogidos, y limitará el acceso 
a toda la información confidencial a sólo los investigadores del estudio. 
 
PRIVILEGIO DE RETIRADA 
Usted puede retirarse del estudio en cualquier momento y por cualquier razón sin pena 
ni perjuicios hacia usted. Su decisión no provocará trato negativo hacia usted por parte 
de los investigadores. 
 
COSTOS Y PAGOS 
Todos los alimentos de la prueba serán dados durante el estudio de forma gratuita. 
Usted recibirá una tarjeta de Target de $ 10 en las visitas de ensayo 1 y 2 y  una tarjeta 
de Target por $15 en las visitas de las pruebas 3 y 4 ($ 50 en total si se completa el 
estudio). 
 
INDEMNIZACIÓN POR ENFERMEDAD Y LESIONES 
Si acepta participar en el estudio, su consentimiento no implicará una renuncia a 
ninguno de sus derechos legales. Sin embargo, en caso de daño, lesión o enfermedad 
que surgiera de este estudio, ni la Universidad Estatal de Arizona, ni los investigadores 
son capaces de darle cualquier cobertura de dinero, seguros, asistencia médica 
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gratuita, o compensación alguna por dicha lesión. Una lesión grave no es probable, pero 
si es necesario, se hará una llamada al 911. 
 
CONSENTIMIENTO VOLUNTARIO 
Cualquier pregunta que tenga sobre el estudio de investigación o su participación en el 
estudio, antes o después de su consentimiento, será contestada por la Dra. Carol 
Johnston; 500 N. 3rd Street Phoenix, AZ 85004; 602-827-2265. 
 
Si usted tiene preguntas acerca de sus derechos como sujeto/participante en esta 
investigación, o si usted siente que ha sido puesto/a en situación de riesgo, puede 
ponerse en contacto con el Presidente de la Junta de Revisión Institucional de Sujetos 
Humanos, a través de la Oficina de Cumplimiento de Investigaciones de ASU, en 480-
965 6788. 
 
Este formulario explica la naturaleza, las demandas, los beneficios y los riesgos del 
proyecto. Al firmar este formulario, usted acepta a sabiendas de asumir cualquier riesgo 
involucrado. Recuerde que su participación es voluntaria. Usted puede optar por no 
participar o retirar su consentimiento y dejar de participar en cualquier momento sin 
penalidad o pérdida de beneficios. Al firmar este formulario de consentimiento, usted no 
renuncia a ningún reclamo, derechos legales o remedios. Una copia de este formulario 
de consentimiento le será entregada a usted. 
 
Su firma indica que usted da su consentimiento para participar en el estudio arriba 
mencionado. 
 
 
__________________   ___________________ ________________ 
Firma del Sujeto  Nombre   Fecha 
 
 
______________________           _________________________       
Teléfono de Contacto              Email    
 
DECLARACIÓN DEL INVESTIGADOR 
"Certifico que he explicado a la persona arriba mencionada de la naturaleza y el 
propósito, los beneficios potenciales y los posibles riesgos asociados con la 
participación en este estudio de investigación, y he respondido a las preguntas que se 
han planteado, y he sido testigo de la firma anterior. Estos elementos de 
Consentimiento Informado se ajustan a la garantía dada por la Universidad Estatal de 
Arizona a la Oficina de Protección de Investigaciones Humanas para proteger los 
derechos de los sujetos humanos. He proporcionado al sujeto/participante una copia de 
este documento de consentimiento firmado ". 
 
 
Firma del Investigator_________________________ Fecha_____________ 
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SAMPLE SIZE 
 The data used to calculate the sample size for this research was based on the results 
of two studies that measured similar outcome variables.  The results used from these two 
studies were describing how effectively antacids treat the symptoms of heartburn for patients 
with gastroesophageal reflux disease (GERD), and this research is to test how effective 
vinegar can alleviate heartburn symptom related to GERD.   
Study A (Hartono,Juanda L. 2011). 
Patients were interviewed and those who experienced heartburn and acid regurgitation more 
than once a week, for the preceding 3 months, were considered for the study.  Both 
symptomatic erosive reflux disease (ERD) and non-erosive reflux disease (NERD) patients 
in this study followed a treatment of Rabeprazole, a proton pump inhibitor, 20 mg twice 
daily for two-week.  The baseline reflux symptom scores (RSS) were assessed prior to and 
after the treatment.   The results of the medication response were shown in the table below. 
Symptomatic response to PPI 
 
Symptomatic ERD (n = 
24) 
NERD (n = 34) p value 
RSS pre-treatment ± 
SD 
15.17 ± 9.09 16.79 ± 10.69 0.716 
RSS post-treatment 
± SD 
1.79 ± 3.67 6.24 ± 6.47 ˂ 0.001 
Mean %∆ RSS ± SD 89.08 ± 21.67 58.53 ± 32.54 ˂ 0.001 
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The NERD group Mean %∆ RSS ± SD value was used to calculate sample size, and there 
were 34 subjects in this group.  Minimal detectable difference in means was 59 and SD was 
33.  The significance level was set at .05 and a power of 0.8.  Using the established formula 
for cross-over study and quantitative measurement, based on the study A data, a total of 8 
subjects are needed for this research. 
Study B (Collings,KL 2002). 
Study B was a single-blind, four treatment cross-over design.  26 subjects who have had 
heartburn symptom for two month or longer were recruited for the study.  Two subjects did 
not have complete data, so only 24 subjects' data were recorded in the result.  Self-
assessment of heartburn severity - 100-point visual analogue scale (VAS) were taken every 5 
minutes after the initiation of the treatment for the first 15 minutes, and at 15-min intervals 
thereafter for the total period of 120 minutes.  Four groups in this study were Placebo, 
chewable antacid (two tablets of calcium carbonate 500 mg ), lower dose antacid gum  (two 
gums each containing 300 mg of calcium carbonate ), and higher dose antacid gum (two 
gums each containing 450 mg of calcium carbonate).  Percent of mean change and standard 
deviations (SD) were not given in the table or the text in the study, so the percent of mean 
change number was obtained through the result figure provided.  The result of lower dose 
antacid gum group was used for calculations.  Mean change  = [50 (mean of the highest 
score of VAS heartburn severity) - 21 (mean of the lowest score of VAS heartburn severity)] 
/ 50 = 0.58 = 58%.  SD was not given by the study, so the largest possible number 58 is 
used for the calculation.  The significance level was set at 0.05 and a power of 0.8.  Using the 
established formula for cross-over study and quantitative measurement, based on the study 
B data, a total of 18 subjects are needed for this research. 
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Based on the calculated sample size of the two studies, approximately 13 subjects are needed 
to optimize the data of this cross-over research for its representative accuracy and its 
application to the general public.  After anticipating a 20% drop-out rate, a total of 15 
subjects are needed for the recruitment.  See the table below. 
Author Year 
Symptomatic 
Response 
Mean% 
change 
N 
per 
Group 
Calculated n 
per group 
Age 
Range 
Subject 
State 
Test 
Hartono et 
al. 
2011 59 34 8 
50.79 ± 
16.02 
NERD 
Mann-
Whitney 
Collings et 
al. 
2002 58 24 18 18-60 GERD ANOVA 
AVERAGE  58 29 13    
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APPENDIX E 
HEARTBURN ASSESSMENT SCALES 
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Please mark the circle below based on your heartburn severity  at the indicating timing on 
the left side of column. 
 None (1) Mild (2) Moderate (3) Severe (4) Very Severe (5) 
Before the meal          
  
Mark this line if 
your heartburn 
starts before 15 
minute marking  
        
  
15 minutes since 
the starting of 
the meal  
        
  
20 minutes since 
the starting of 
the meal  
        
  
25 minutes since 
the starting of 
the meal  
        
  
30 minutes since 
the starting of 
the meal  
        
  
45 minutes since 
the starting of 
the meal  
        
  
1 hour since the 
starting of the 
meal 
        
  
1 hour and 15 
minutes since 
the starting of 
the meal 
        
  
1 hour and 30 
minutes since 
the starting of 
the meal 
        
  
1 hour and 45 
minutes since 
the starting of 
the meal 
        
  
2 hours since the 
starting of the 
meal 
        
  
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